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ABSTRACT 
The focus of this research was to investigate the role of protein kinase C-iota 
(PKC-ι) in the regulation of Bad function, a pro-apoptotic member of the Bcl-2 family 
and Cdk7 function, a master cell cycle regulator in glioblastoma.   
The results were obtained from the human glial tumor derived cell lines, T98G 
and U87MG.  In these cells, PKC-ι co-localized and directly associated with Bad as 
shown by immunofluorescence, immunoprecipitation, and Western blotting.  
Furthermore, in-vitro kinase activity assay showed that PKC-ι directly phosphorylated 
Bad at phospho specific residues, S112, S136 and S155 which in turn induced 
inactivation of Bad and disruption of the Bad/Bcl-XL dimer.  Knockdown of PKC-ι by 
siRNA exhibited a corresponding reduction in Bad phosphorylation suggesting that PKC-
ι may be a Bad kinase.  Since, PKC-ι is an essential downstream mediator of the PI (3)-
kinase, we hypothesize that glioma cell survival is mediated via a PI (3)-
kinase/PDK1/PKC-ι/Bad pathway.  Treatment with PI(3)-kinase inhibitors Wortmannin 
and LY294002, as well as PDK1 siRNA, inhibited PKC-ι activity and subsequent 
phosphorylation of Bad suggesting that PKC-ι regulates the activity of Bad in a PI (3)-
kinase dependent manner.   
Robust expression of PKC-ι is a hallmark of human glioma and benign and 
malignant meningiomas, however, little is understood about its role in glioma cell 
proliferation. The cyclin dependent kinase activating kinase complex (CAK), comprises 
of cyclin dependent kinase 7 (Cdk7), cyclin H and MAT1, is the master cell regulator. 
x 
 
Cdk7 phosphorylates its downstream cyclin dependent kinases (cdks) and promotes cell 
proliferation.  Results show that PKC-ι directly associated and phosphorylated Cdk7 at 
T170.  Furthermore, Cdk7 phosphorylated its downstream target, cyclin dependent kinase 
2 (cdk2) at T160.  Purified PKC-ι was also observed to phosphorylate endogenous as 
well as exogenous Cdk7.  PKC-ι knockdown with siRNA, PDK1 siRNA and (PI) 3-
kinase inhibitors, Wortmannin and LY294002 treatment exhibited corresponding 
reduction in phosphorylation of Cdk7 and subsequently cdk2.  In addition, PKC-ι 
knockdown reduced cell proliferation; led to cell cycle arrest and also induced apoptosis.  
Thus, these findings suggest the presence of a novel PI (3)-kinase/PKC-ι/BAD mediated 
cell survival and PI (3)-kinase/PKC-ι/Cdk7 mediated cell proliferation pathway. 
 
1 
 
 
 
CHAPTER 1 
INTRODUCTION 
1.1 Project hypothesis 
An activated PKC-ι dependent anti-apoptotic pathway drives the cell cycle 
proliferation and survival of glioma cells.  
1.1.1 Main objective.  PKC-ι is shown to be involved in tumor proliferation, 
angiogenesis, invasion, cell survival as well as chemoresistance in several types of 
cancers [1-5].  Although, PKC-ι is implicated to be involved in these cellular events, its 
mechanism has not been completely studied.  We initiated a study to examine the effect 
of PKC-ι overexpression and/or aberration in glioma cell survival and proliferation.  
T98G (p53 mutated) and U87MG (PTEN null) are Grade IV metastatic human tumor 
derived glioma cells.  Mutations of similar nature are commonly observed characteristics 
in glioblastoma[6].  Therefore, understanding the signaling mechanism by which such 
uncontrolled cell progression and proliferation occur may help diagnose the disease 
earlier and aid in improving long term survival of glioblastoma patients.  In the current 
study, our main aim was to determine whether PKC-ι was highly activated and whether it 
is crucial for glioma cell proliferation and survival.
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1.2 Glioma 
1.2.1 Overview.  Brain tumors are the biggest challenges of all cancers since they 
destroy the most important part in the body.  Brain tumors are known to be the second 
most common cause of cancer-related death in people in their old age.  Each year 1 of 
every 5,000 people in the age group 35- 60 years develops a brain tumor.  Brain tumors 
are the most common form of solid tumor in children [7].  The incidence of brain tumor 
is higher in men than in women.  The American Cancer Society estimates that there are 
more than 18,000 new diagnoses of brain and nervous system cancers causing more than 
12,000 deaths each year in the United States [8].  Among all age groups, survival of 
younger patients was significantly longer with a range from a median of 8.8 months (<50 
years) to 1.6 months (>80 years) [6, 9]. 
1.2.2 Types of brain tumors.  Brain tumor, in common term has long been 
understood as a tumor of brain as a whole. However, it is interesting to note that 
according World Health Organization, there are about 126 different types of brain and 
spinal cord tumors. [10].  Each and every part of brain and spinal cord are susceptible to 
tumor formation (Fig 1).There are two main categories of brain tumor – (i) Primary 
tumors are of two types (a) Benign (b) Malignant and (ii) Secondary (metastatic) brain 
tumors - originate from the malignant tumors of other body parts.  They can be classified 
according to cell type, by grade and by location (Table 1). 
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1.2.3 Symptoms. Glioma symptoms depend on which part of the central nervous 
system is affected. Glioma of the brain can cause headaches, nausea and vomiting, 
memory loss, language deficit, seizures and cranial nerve disorders due to aggravated 
intracranial pressure. Optic nerve glioma can cause visual loss. Spinal cords gliomas can 
cause pain, weakness, or numbness 8 in the extremities [ ].  
          
Figure 1 Parts of the brain and spinal cord.
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Table 1 WHO Classification of Primary brain tumors. 
Tumors  Grade Type 
Neuroepithelial tumors 
1. Astrocytic tumors  
a Pilocytic astrocytoma  I Benign 
b Subependymal giant cell astrocytoma I Benign 
c Diffuse astrocytoma II Benign 
d Pleomorphic xanthoastrocytoma II Benign 
e Anaplastic astrocytoma  III Malignant 
f Glioblastoma IV Malignant 
 
2. Oligodendroglial tumors 
a Oligodendroglioma II Benign 
b Anaplastic oligodendroglioma  III Malignant 
 
3. Oligoastrocytic tumors 
a Oligoastrocytoma II Benign 
b Anaplastic oligoastrocytoma  III Malignant 
 
4. Other neuroepithelial tumors 
a Angiogenic glioma I Benign 
b Chordoid glioma of the third ventricle II Benign 
  
5. Neuronal and mixed neuronal-glial 
tumors  
I-III Low-high 
6. Pineal tumors I-IV Low-high 
7. Embryonal tumors  IV Malignant 
 
Tumors of cranial and paraspinal nerves 
1. Schwannoma  I Benign 
2. Neurofibroma  I Benign 
3. Perineurioma I-IV Low-high 
4. Malignant peripheral nerve sheath 
tumor 
II-IV Low-high 
 
Tumors of the meninges 
1. Meningioma (benign) I Benign 
2. Atypical meningioma II Benign 
3. Anaplastic meningioma  III Malignant 
Lymphomas and hematopoietic neoplasms I-III Low-high 
Tumors of the sellar region I Benign 
Information from reference [11]
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1.2.4 Treatment strategy.  Every part of brain plays a very delicate yet highly 
complex function which makes surgical removal of this organ impossible. Brain tumors 
are found in the tissue inside the skull that leaves very little room for tumor growth 
without compressing or damaging the normal brain. This can disrupt the blood-brain 
barrier which then presses onto the sensitive tissue, blocking the flow of blood and other 
fluid causing pain and inflammation leading to necrosis thereby ruining the neurological 
functions of the brain.  Thus, treatment of gliomas depends on the cell type, location and 
grade of malignancy (histopathology) [12].   
Often, treatment is a combinatorial approach using surgery, radiation therapy and 
chemotherapy.  (A) Surgery
13
 - Even though it is difficult to perform surgery on the brain 
tissue, surgery still is usually the first treatment in brain tumor. It is generally a treatment 
of choice for primary brain tumor if the subject is a candidate for complete resection. 
Surgery is often curative for intracranial tumors that occur outside the brain, such as 
pituitary adenomas, schwannomas, and meningiomas [ , 14].  (B) Radiation therapy
15
 - 
Radiation therapy post-surgical resection is a standard therapy for high-grade gliomas. 
Radiation can be delivered by external or internal methods.  External beam radiation can 
be conventional or stereotactic radiosurgery [ ]. The dosage of treatment depends on the 
location, grade, histology and extent of resection. Interstitial radiotherapy 
(brachytherapy) is also prescribed however it involves surgically implantation of the 
radioactive material directly inside the tumor.  (C) Chemotherapy - Recent studies in 
signaling mechanisms have shown new therapeutic targets and development of 
chemotherapy against these targets have slightly improved the management of primary 
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brain tumors.  Identifying and targeting these important down-stream mediators and 
combining chemotherapy with radiation may improve survival in high grade gliomas [16, 
17]. Temozomide in combination with radiation has shown a positive response against 
high-grade gliomas [18]. Agents like irinotecan (Camptosar) and targeted agents such as 
bevacizumab (Avastin), which targets the vascular endothelial growth factor; and 
gefitinib (Iressa), erlotinib (Tarceva), and imatinib (Gleevec), which target the epidermal 
and platelet-derived growth factor receptors, have shown some promise in the treatment 
of recurrent malignant gliomas [19]. 
1.2.5 Overview of Glioblastoma.  Glioblastoma Multiforme is the most lethal of 
brain tumors as it infiltrates the entire central nervous system (CNS) and may develop de 
novo (primary glioblastoma) or by progression from low-grade astrocytoma (secondary 
glioblastoma) (Table 2).  Glioblastoma Multiforme is labeled as a Grade IV Astrocytoma.  
It comprises of more than 25% of all primary brain tumors [7, 20].  Adults are known to 
be more prone to brain tumor in comparison to children.  Its infiltrative nature makes is 
highly incurable. Glioblastoma patients typically show Loss of Heterozygosity (LOH) on 
chromosome 10q, genetic alterations such as epidermal growth factor receptor (EGFR) 
amplification, tumor protein 53 (TP53) mutation, p16INK4 deletions and phosphatase and 
tensin homology (PTEN) mutation [21].  Surgical removal of the tumor in most cases 
seems to increase survival time but generally the tumor spreads throughout CNS which 
makes its recurrence very obvious.  Radiation therapy has induced more toxic effects on 
the brain and its surrounding tissue instead of curing it [15].  Glioblastoma is found to be 
highly resistant to most chemotherapeutic treatment as well, although, drugs like 
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Temozolomide have been shown to increase survival in patients with high grade 
glioblastoma [18].   
Table 2 Genetic pathways leading to primary and secondary glioblastomas  
Type of glioblastoma Type of mutation % prevalence WHO grade 
 
Low-grade astrocytoma TP53 mutation 59 II 
    
Anaplastic astrocytoma TP53 mutation 53 III 
 
 
Primary glioblastoma 
(de novo) 
LOH 10q 70  
IV EGFR amplification 36 
p16INK4a deletion 31 
TP53 mutation 28 
PTEN mutation 25 
 
 
Secondary glioblastoma 
LOH 10q 63  
IV EGFR amplification 8 
p16INK4a deletion 19 
TP53 mutation 65 
PTEN mutation 4 
Information from reference [6]. 
 
1.3 Protein kinase C 
1.3.1 Overview.  Protein kinases are main controllers of cell function which by 
adding phosphate groups to the downstream molecules regulate the signaling cascade.  
Protein kinases can be classified into (i) serine/threonine protein kinases - which 
phosphorylate serine or threonine residues, (ii) protein tyrosine kinases
22-25
 - which 
phosphorylate tyrosine residues.  Protein kinase C (PKC) is one of the primary protein 
kinases discovered.  PKC is a family of 12 or more related serine/threonine kinases which 
are important targeted mediators in signal transduction mechanism [ ].
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1.3.2 PKC isozymes.  PKC can be divided into three main groups of isozymes 
depending on their protein structures as well as their requirement of specific activators 
and co-factors (i) the conventional PKC isozymes -alpha (α), beta I (βI), beta II (βII) and 
gamma (γ) are dependent on calcium, diacylglycerol (DAG) and phospholipids, (ii) the 
novel PKC isozymes - delta (δ), epsilon (ε), eta (η) and theta (θ) are calcium independent 
but dependent on DAG and phospholipids, (iii) the atypical PKC isozymes - PKC zeta (ζ) 
and PKC iota (ι) in humans/ lambda (λ) in mouse are insensitive to calcium and DAG.  
An additional family member has been introduced into the PKC family, Protein Kinase 
D, mu (μ) [26]. Another, distant related family member includes PKC-related kinases 
(PRK 1-3), known as PKN [27] (Table 3).   
1.3.3 Structure of Protein kinase C.  Protein kinase C family members are made 
up of a single polypeptide chain (Fig 2). Primary structure of PKC consists mainly of 
regulatory domain (NH2 terminal, approximately 20 - 40 kDa) involved in the binding of 
phorbol esters and Ca2+ [28] and a catalytic domain (COOH terminal, approximately 45 
kDa) involved in ATP and substrate binding.  Conventional PKCs and Novel PKCs have 
two tandem repeats of these motifs called C1A and C1B involved in the binding of 
second messenger DAG and phorbol esters as well as membrane lipids [29, 30].  C2 
domain is the Ca2+ binding domain involved in the activation of conventional PKCs [31, 
32]. Novel PKCs have a C2-like domain but are not regulated by Ca2+ and thus utilize 
protein-protein interactions for activation [33].  Atypical PKCs lack the residues for Ca2+ 
binding C2 domain but comprise of an additional PB1 domain which is known to 
function in protein-protein interaction [34].
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The catalytic domain (45kDa) is structurally similar amongst all the PKC 
isozymes made up of two lobes. It is also 40% identical to the kinase domain of protein 
kinase A (PKA) and protein kinase B (AKT).  Phosphorylation at kinase domain and 
release of pseudosubstrate from the regulatory domain are required for activation of PKC 
which opens the frame for substrate binding at the catalytic site [35]. 
1.3.4 Protein kinase C regulation.  Protein kinase C becomes catalytically 
competent as well as localized intracellularly by a cascade of three orchestrated 
phosphorylations [36] (Fig 3). The first step in the maturation of PKC is phosphorylation 
at the entrance of the kinase core called activation loop.  Phosphoinositide-dependent 
kinase -1 (PDK-1) has been shown to act upstream of PKC and triggers this step [37].  
This initiates autophosphorylation at the tip of the kinase domain turn known as the turn 
motif.  It is important for the maturation of PKC; for protein-protein interaction and for 
initiating the mechanism of docking the enzyme to the membrane.  PKC is then localized 
into the cytosol and upon extracellular stimulation, phospholipase C mediated breakdown 
of phosphatidylinositol into phosphatidylinositol (3)- kinase (PI(3)-kinase) and in the 
presence of co-factors, a conformational change is triggered resulting in the protein 
releasing the auto-inhibitory pseudosubstrate [38].  Subsequently, PKC undergoes 
autophosphorylation at hydrophobic motif [39].  The primary role of this phosphorylation 
site is to stabilize the protein from proteolytic degradation [40].   
PKC function is dependent upon its correct distribution and localization in the 
cells.  PKC interacts with certain anchoring proteins such as RACKS (receptors for 
activated C- kinase) or STICKs (substrates that interact with C-kinase) whose functions 
are (i) bring PKC isozymes in close proximity with their regulators and substrates, (ii) 
10 
 
help in translocation of newly synthesized PKCs to the plasma membrane and (iii) help in 
binding the PKC cofactors [41-44].  Most PKCs are ubiquitously present in most tissues 
but each PKC differs in their substrate specificity and co-factor activation. There are 
several activators of PKCs known till date, some of which are mentioned in Table 4. 
 
 
 
Figure 2 Primary Structure of Protein Kinase C and its members.  Depicted in the figure are 
pseudosubstrate (PS, green), cysteine-rich domain (C1A and C1B, purple), calcium-binding domain (C2, 
yellow), protein:protein interaction motif (PB1, dark red), transmembrane domain (SP/TM, pink), 
pleckstrin homology domain (PH, orange),  kinase domains (C3, C4, light blue) consists of 3 phospho 
residues for each PKC isozyme (Adapted from [45]).
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Table 3 PKC isozymes and their size distribution 
 
Adapted from [46].
PKC isozymes Mw  (kDa) Amino Acids Source Tissue distribution 
Conventional PKC isozymes 
alpha (α) 76.8 672 human Ubiquitous 
beta I (βI) 76.9 673 human 
omnipresent in most 
tissues 
beta II (βII) 76.8 671 human 
omnipresent in most 
tissues 
Novel PKC isozymes 
gamma (γ) 78.4 697 human neural 
delta (δ) 77.5 673 rat ubiquitous 
epsilon (ε) 83.5 737 rat ubiquitous 
eta (η) 77.6 680 human neural, epithelium 
theta (θ) 82.0 706 Human 
ovary, skeletal 
muscle, platelets 
Atypical PKC isozymes 
zeta (ζ) 67.7 592 Rat 
omnipresent in most 
tissues 
iota (ι)/ lamda (λ) 67.2 586 
human/
mouse 
ubiquitous 
Protein Kinase D 
mu (μ) 115 912 mouse Unknown 
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Figure 3 PKC activation motifs.(adapted from [24]) 
 
 
Table 4 PKC activators 
 Conventional PKCs  Novel PKCs Atypical PKCs 
 
 α βI βII γ δ ε η θ ζ ι 
PS + + + + + + + + + + 
DAG + + + + + + + + - - 
Ca2+ + + + + - - - - - - 
FFA + + + + + + + ? + + 
LysoPC + + + + + + + ? + + 
 
Adapted from [47-51].
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1.4 Phosphatidylinositol (3)-kinase  
 Atypical PKC-ι is activated by phosphatidylinositol (3)-kinase (PI (3)-kinase) 
through phosphorylation and activation of phosphatidylinositol dependent kinase (PDK-
1) 
1.4.1 Overview.  Phosphatidylinositol 3-kinases are a family of enzymes that play 
a pivotal role in regulating important cellular mechanisms.  PI (3)-kinases are capable of 
generating lipid second messengers by phosphorylating the 3' hydroxyl group of 
phosphoinositide lipids (PIs).  PI (3)-kinases are at the heart of major intracellular signal 
transduction pathways.  The signals transduced by PI (3)-kinase are known to influence 
numerous biological processes including cell growth, differentiation, survival, 
proliferation, migration, glucose metabolism, cytoskeletal organization amongst few.  
Dysregulation of these pathways can lead to cancer [52]. Evidence suggests that many 
steps in PI (3)-kinase signaling cascade are known to be mutated, upregulated, 
overexpressed or hyperactivated in human cancers [53-56]  
1.4.2 Classes of PI (3)-kinase.   The PI3K family is divided into three classes 
termed I, II, and III.  They are divided on the basis of their structural similarities, 
regulation and substrate specificity.   
All human class I members are heterodimers consisting of a catalytic subunit 
(MW approx. 110 kDa) and a non-catalytic subunit (MW 50, 55, 85, 87 or 101 kDa).  
Class I members are further subdivided into class IA and IB PI (3)-kinases.  Class IA 
comprises three isoforms (p110α, p110β and p110δ) whereas the only class IB member is 
termed p110γ. [57, 58].  Class I catalyze the production of phosphotidylinositol 3-
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phosphate (PI (3) P), phosphotidylinositol 3, 4-bisphosphate (PI (3, 4) P2), 
phosphotidylinositol 3, 4, 5-trisphosphate (PI (3, 4, 5) P3) from phosphotidylinositol (PI).  
Class II consists of three catalytic isoforms (C2α, C2β, and C2γ), but, unlike 
Classes I and III, there are no regulatory proteins. Class II catalyze the production of PI 
(3) P and PI (3, 4) P2 from PI.  The C-terminal C2 domain of PI 3-kinases lacks critical 
Asp residues to coordinate binding of Ca2+, which suggests class II PI3Ks bind lipids in a 
Ca2+-independent manner. 
Class III proteins catalyzes only PI (3) P from PI; however, it is more similar to 
Class I in structure.  They exist as heterodimers of a catalytic (Vps34) and a regulatory 
domain (Vps15/p150)  
There are a more distantly related group of enzymes that are often referred to as 
class IV PI 3-kinases. The class IV PI 3-kinases family contains ataxia telangiectasia 
mutated (ATM), ataxia telangiectasia and Rad3 related (ATR), mammalian target of 
rapamycin (mTOR) and DNA-dependent protein kinase (DNA-PK) [59].  
1.4.3 Mechanism of action of PI (3)-kinase and its implication in cancer.  Kinases 
such as AKT, PDK1, PKC contain a pleckstrin homology (PH) domain which enables 
them to bind to (PI (3, 4, 5) P3) and (PI (3, 4) P2) which are produced by activated PI 3-
kinase.  This translocates the kinase to the plasma membrane. The co-localization of 
activated PDK1 and AKT (or PKC) allows AKT to be phosphorylated at T308 leading to 
partial activation of AKT.  Full activation of AKT occurs upon phosphorylation at S473 
by other upstream kinases (Fig. 4).  Several other downstream kinases are activated by a 
similar PI (3)-kinase mechanism.  
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The PI (3)-kinase/AKT signaling mechanism had been shown to be required for 
various cellular activities such as cellular proliferation and survival. The lipid 
phosphatase, PTEN, antagonizes this process by dephosphorylating (PI (3, 4, 5) P3) to 
inhibit activation of AKT (Fig. 4).  PTEN in the cell is frequently observed to be altered, 
mutated or deleted in cancers.  PI (3)-kinase activation is tightly regulated by various 
receptor tyrosine kinases (RTKs) and thus a slight modulation in the receptor activity can 
multiply PI (3)-kinase activity.  EGFR is an upstream activator of PI (3)-kinase and is 
frequently upregulated in cancer [60].  HER2 is another member of the EGFR family 
(activator of PI 3-kinase), is often over-expressed due to gene amplification or 
transcriptional deregulation in breast and ovarian carcinomas [61].  Mutations in multiple 
AKT isoforms have been reported in several cancer models [54]. 
 
 
Figure 4 PI3-kinase signaling mechanism  RTK recruits PI3-kinase directly or through the binding of 
protein GAB, catalyzes the conversion of (PI (3, 4) P2) to (PI (3, 4, 5) P3) which activates AKT to induce 
growth, proliferation and survival. PTEN negatively regulates AKT activation by converting (PI (3, 4, 5) 
P3) to (PI (3, 4) P2). All major proteins involved in this cascade are observed to be altered in cancer. [60]
16 
 
1.4.4 Inhibitors of PI (3)-kinase.  Some of the inhibitors of PI (3)-kinase are 
mentioned in Table 1.  Inhibitors have also been developed against downstream 
substrates to PI (3)-kinase [62] (Table 5).  
 
Table 5 Some inhibitors of PI (3)-kinase 
Inhibitor Type of drug Inhibition profile IC50 
concentration 
 
 
Wortmannin 
- Cell permeable 
- Potent and 
selective 
- Irreversible  
 
- PI (3)-kinase 
 
5nM 
 
LY294002 
- Cell permeable 
- Potent and 
selective 
 
- PI (3)-kinase 
 
1.4µM 
 
Quercetin 
- Flavinoid 
- Potent 
- Mitochondrial ATPase 
- Phosphodiesterase 
- PI (3)-kinase 
 
 
3.8µM 
 
Myricetin 
- Flavinoid (differs  
from Quercetin) 
- Potent 
- α-glucosidase 
- glyoxalase I 
- xanthine oxidase 
- PI (3)-kinase 
 
 
1.8µM 
 
Staurosporine 
 
- Cell permeable 
- potent 
- Protein Kinase C 
- Protein Kinase A 
- CaM kinase 
- myosin light chain 
kinase 
- PI (3)-kinase 
 
 
9µM 
 
Adapted from reference [63-65]. 
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1.5 Bcl-2 family 
 PKC-ι phosphorylates and inactivates the function of Bad, a pro-apoptotic 
member of the Bcl-2 family to promote glioma cell survival. 
1.5.1 Overview.  A variety of death signals due to physiological and pathological 
cellular abuse, trigger the genetically programmed apoptotic pathway [66].  Apoptosis 
induces two major execution programs downstream of the death signal: the caspase 
activation and organelle dysfunction, of which mitochondrial dysfunction is the best 
described [67, 68].  BCL-2 family members are primarily involved in death response and 
play a pivotal role in deciding whether a cell will live or die, manifesting far reaching 
implication in tumor biology.  The Bcl-2 proto-oncogene, the first anti-death gene was 
discovered at the chromosomal breakpoint of t(14;18) in follicular lymphomas [69]. 
1.5.2 Members of the Bcl-2 family.  The members of the Bcl-2 family can be 
divided into three sub-families- (i) Bcl-2 subfamily – Bcl-2, Bcl-XL, Bcl-w and Mcl-1 
are anti-apoptotic, (ii) Bax subfamily – Bax, Bak and Bok and (iii) BH3 subfamily – Bad, 
Bid, Bik, Hrk, BNIP3, PUMA, NOXA and BimL (Fig. 5). Upon stimulation by 
extracellular death signal, all BH3 only proteins interact with Bcl-2/Bcl-XL molecules 
and modulate their survival function [70-73] (Fig. 5)  
1.5.3 Basic features and regulation of Bcl-2 family.  The Bcl-2 (B cell lymphoma-
2) family proteins are vital regulators of the mitochondrial cell death machinery.  Bcl-2 
gene codes for a 25kDa protein which resides on the cytoplasmic face on the 
mitochondrial membrane, the nuclear envelope and endoplasmic reticulum.  Bcl-2 family 
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of proteins has expanded substantially and consists of both pro and anti-apoptotic 
molecules.  The ratio between these two subsets is the deciding factor, in part, the 
susceptibility of cells to death signals.  The members form homo and/or heterodimers to 
execute their action as well as to compete and titrate one another’s function [67].   
Figure 5 Summary of anti-apoptotic and pro-apoptotic Bcl-2 family members.  
Adapted from Reference [74].
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The members of the Bcl-2 family share one or more Bcl-2 homology (BH) domains 
(named BH1, BH2, BH3 and BH4).  These BH domains are critical as they define the 
characteristic function of a particular family member.  Many anti-apoptotic members 
have conserved sequence homology in all four BH domains whereas pro-apoptotic are 
less conserved and differ in their sequence homology.  Characterization of BH domains 
amongst Bcl-2 family members is shown in Table 6.  Several BCL-2 family members 
contain a carboxy-terminal hydrophobic helix, which is essential for docking to 
membranes such as the mitochondrial outer membrane. The Bcl-2 gene members are 
regulated on the transcriptional level upon the cell receiving several survival signals from 
cytokines. Furthermore, the function of Bax is modulated by p53.  Bcl-2 family members 
are also regulated by post -translational modifications such as phosphorylation and 
ubiquitination [73]. 
1.5.4 Overview of Bad and its mechanism of action.  Bad, (Bcl-2 associated death 
promoter) is the pro-apoptotic molecule of the BH3 only molecule of the Bcl-2 family 
involved in initiation of apoptosis.  Unlike other Bcl-2 family BH3 only proteins, Bad 
lacks the hydrophobic C-terminal domain required for mitochondrial outer membrane and 
nuclear envelop targeting.  Bad activity is dependent on three prime residues – Ser112, 
Ser136 and Ser155 [75].  Upon external death signals (eg., IL3 deprivation), these 
residues remain dephosphorylated which enables Bad to associate with Bcl-2/Bcl-XL and 
quench their anti-apoptotic function [72]. 
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To date, several survival kinases such as Akt (PKB), PKC, PKA, Ras, p70S6K 
and PAK are known to phosphorylate these residues deactivating and disrupting Bad/Bcl-
XL dimerization [76].  Dissociated Bad further binds to 14-3-3 scaffold protein and is 
subsequently degraded by proteosomal ubiquitination [77].  Thus, phosphorylation and 
dephosphorylation can alternate the binding target of Bad, modulating its pro-apoptotic 
function.  An imbalance among the Bcl-2 family of proteins with more dependency on 
the anti-apoptotic members is often observed to occur in cancer cells [78, 79] (Fig. 6). 
 
 
Figure 6 Mechanism of action of Bad, a pro-apoptotic molecule of Bcl-2 family protein.
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Table 6 Bcl-2 family of proteins and their domains  
Bcl-2 family and their domains 
 BH1 BH2 BH3 BH4 Transmembrane 
(TM) 
Bcl-2 subfamily (anti-apoptotic) 
Bcl-2 + + + + + 
Bcl-XL + + + + + 
Bcl-w + + + + + 
Mcl-1 + + + - + 
 
Bax subfamily (multi-domain pro-apoptotic) 
Bax + + + - + 
Bak + + + - + 
Bok + + + - + 
 
BH3 subfamily (pro-apoptotic) 
Bad - - + - - 
Bid - - + - - 
Bim - - + - + 
Hrk - - + - + 
PUMA - - + - - 
NOXA - - + - - 
Bik - - + - + 
 
  Adapted from [74]
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1.6 Cyclin-dependent kinases  
 PKC-ι associates, phosphorylates and activates cyclin dependent kinase (CDK) 
activity thereby regulating glioma cell cycle progression and proliferation. 
1.6.1 Overview.  Cyclin-dependent kinases (CDKs) are a family of protein 
serine/threonine kinases that play an important role in the molecular machinery that 
regulates the cell cycle [80].  CDK activity is tightly regulated throughout the cell cycle 
by complicated mechanisms including the binding of regulatory proteins and the 
phosphorylation/dephosphorylation of CDKs which controls the completion of one phase 
before progressing to the next phase [81].  In addition to the control of cell division and 
transcription, CDKs also regulate cell differentiation and apoptosis.  CDKs also play an 
essential part in neuronal events of the CNS leading to differentiation, migration, 
degeneration and apoptosis [82, 83].  CDKs are present in all eukaryotic cells and are 
evolutionarily conserved. 
1.6.2 Types of CDKs.  CDKs are relatively small proteins, approximately 35-
42kDa.  They are regulated by proteins called cyclins without which CDKs have finite 
kinase activity.  The consensus sequence for the amino acid sequence in a CDK substrate 
is [S/T*]PX[K/R], where S/T* is the serine or threonine phosphorylation residue, P is 
proline, X is any amino acid, K is lysine and R is arginine [84].  The primary role of these 
Cdk-cyclin complexes is to regulate the progression through the cell cycle. There are 
approximately nine mammalian CDKs (Table 7), of which, four Cdks, Cdk1, 2, 3 and 4 
are directly involved in cell cycle regulation and progression (Fig. 7 and Table 8).  
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Table 7 Types of CDKs and their cyclin partners and functions  
CDKs Cyclin partner Function 
Cdk1 Cyclin B M phase 
Cdk2 Cyclin E G1/S transition 
Cdk2 Cyclin A S phase, G2 phase 
Cdk3 Cyclin C G1 phase, ? 
Cdk4 Cyclin D G1 phase 
Cdk5 p53 Transcription 
Cdk6 Cyclin D G1 phase 
Cdk7 Cyclin H CDK-activating kinase, 
transcription 
Cdk8 Cyclin C Transcription 
Cdk11 Cyclin L ? 
? Cyclin F ? 
? Cyclin G ? 
Adapted from reference [85] 
1.6.3 Regulation of CDKs.  CDK levels are significantly constant throughout the 
cell cycle however their activity is regulated by various mechanisms. CDKs are regulated 
by four main mechanisms, binding of cyclins, CAK phosphorylation, inhibitory 
phosphorylations and binding of either of the two major CDK inhibitory family (CKIs) –  
INK4 family or Cip/Kip family [81]. 
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Figure 7 CDKs, their cyclin partners in different cell cycle phases. 
 
Table 8 CDKs and their cyclin partners in cell cycle phases 
CDKs Cyclin partners Cell cycle phases 
Cdk3 C G0 
Cdk4, Cdk2, Cdk6 D, E G1 
Cdk2 A, E G2 
Cdk2, Cdk1 A S 
Cdk1 B M 
     Adapted from reference [84, 85]
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1.6.4 Role of Cdk7.  Amongst all Cdks, Cdk7 is the master cell cycle regulator as it 
has the ability to regulate the activities of other Cdks by phosphorylating their activation 
loop thus initiating the mammalian cell cycle [86].  It is part of a trimeric CAK (cyclin 
dependent kinase activating kinase) complex (comprising of Cdk7, cyclin H and MAT1) 
which stabilizes and activates Cdk7.  Cdk7 is the only eukaryotic CAK known till date 
[87].  This trimeric complex subsequently phosphorylates downstream cdks on their 
activation segment inducing their activity [88].  Studies have shown that Cdk7 levels are 
low in cells and are predominantly located in the nucleus [89].  Cdk7 also helps in the 
regulation of transcription as part of the transcription factor TFIIH complex by 
phosphorylating RNA polymerase II (RNA pol II) large subunit C-terminal domain 
(CTD) [90].  Cdk7 particularly phosphorylate Ser-5 and this phosphorylation on the CTD 
facilitates promoter recognition, initiation of transcription and RNA processing enzymes 
[91].  Cdk7 has two phosphorylation sites.  The primary phosphorylation site at the 
conserved T-170 on the T-loop induces stable dimerization with cyclin H. The secondary 
phosphorylation at Ser164 on the activation segment further stabilizes the complex [92].  
The trimeric complex is active in the absence of Cdk7 phosphorylation however 
phosphorylation stabilizes the complex leading to its further activation [93]. One key 
residue Lys-166 is conserved amongst most Cdks, cdk2, cdk1, cdk4, cdk5 and cdk6 and 
may be a main requirement for these cdks to be a substrate for Cdk7.  Structural and 
biochemical studies have proved that cdk2 is an in-vitro substrate to Cdk7 [87].
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1.6.5 Role of cdk2.  Cdk2 is a prime regulator of G1 to S phase transition in cells. 
Cyclin E/cdk2 have important roles in not only regulating the cell cycle phase but also in 
centrosome duplication [94].  Research shows that cdk2 exerts its biological activities by 
phosphorylating its substrates probably at the RXL motif coinciding with cyclin binding 
[95].  A number for cdk2 substrates are identified which regulate cell division and few of 
them are mentioned below:   
- Cdk2 mediated phosphorylation of Rb, inactivates Rb by derepressing E2F 
transcription factor [96].   
- Cdk2 induces phosphorylation of p27 which stimulates its degradation by SCF-
Skp2 ubiquitin ligase [97].  
- Cdk2 phosphorylates NPAT which promotes histone transcription (cells without 
NPAT cease to enter S phase from quiescence) [98].  
- Cdk2 phosphorylates CBP/p300 at G1/S transition to activate its histone 
acetyltransferase activity which also functions as a co-factor for many 
transcription factors such as E2F [98].   
- Cdk2 co-operates with cdc6 to allow formation of pre-replication complexes 
during G1/S transition [99].  
- Cdk2 also phosphorylates MCM family members, MCM2 and MCM3 that play 
essential roles in eukaryotic DNA replication [100].
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1.6.6 Implications of CDKs in cancer.  Abnormal activation or loss of function of 
CDKs and their regulators have great impact in human cancers [101].  Such adverse 
transformation or molecular changes in cells can modulate the tightly regulated 
progression of the cell cycle their checkpoints at the G1-S and G2-M transitions [80, 
102].  As shown in Fig 6. CDKs and their cyclin partners are predominantly involved in 
cell cycle phase transition and any insults on this cascade can have undesirable 
repercussions on the cell machinery.  Its unfavorable effects have been seen in many 
cancer models leading to uncontrolled cell proliferation, cell survival, migration and 
angiogenesis. 
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CHAPTER 2 
PKC-ι IS OVEREXPRESSED IN GLIOBLASTOMA 
2.1 Overview 
Inherent over expression of protein kinase Cs (PKC) [103, 104] is a characteristic 
of many cancers.  Several studies show that PKC hyperactivity is concordant with the 
malignant growth rates in gliomas.  The atypical PKCs-ι and ζ- are stimulated by protein-
protein interaction and by phospholipids that are involved in mechanistic pathways that 
control cellular responses such as growth, proliferation, survival and apoptosis [105].  
PKC-ι  and ζ are targeted mediators in the PI (3)-kinase signal transduction repertoire 
[106].  PKC-ι is the most common genomic amplicon as identified by comparative 
genomic hybridization and has been recognized as an oncogene [107-109].  It stimulates 
cell survival and prevents apoptosis in non small cell lung cancer (NSCLC), prostate 
cancer and gastric carcinoma [2, 4, 110].  PKC-ι hyper-activation is also responsible for 
chemoresistance in chronic myelogenous leukemia cells and glioblastoma [1, 3].   
Although, several studies have shown that PKC-ι (an atypical isoform of PKC 
family) is a key regulator of invasion, metastasis and chemoresistance in glioblastoma [3, 
111, 112], the endogenous expression of PKC-ι in glioblastoma remains obscure and 
thus, we initiated a study to investigate the role of PKC-ι in glioblastoma. In the current 
study, T98G and U138MG cells were used to explore the expression and importance of 
PKC-ι in glioblastoma. T98G (CRL-1690), U138 (HTB-16) and U87MG (HTB-14) cells 
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were obtained from the American Tissue Culture Collection (Rockville, MD, USA).  The 
T98G cell line was isolated by Stein, 1979 [113] as a spontaneous variant of the parental 
T98G cells which were derived from a glioblastoma multiforme tumor of a 61-year-old 
Caucasian male.  The cells have a hyperpentaploid chromosome count and display 
immortality but are not tumorigenic in nude mice.  The doubling time for T98G cells is 
approximately 18 hours.  The trait that distinguishes T98G cells from fully transformed 
cells is that they behave similarly to normal cells and can become arrested and stationary 
in G1phase [114].  U-138MG cells were originally isolated and established into a stable 
cell line by Ponten & MacIntyre, 1968 [114], having been derived from an astrocytoma-
glioblastoma (grade III) of a 47-year-old Caucasian male. 
2.2 Results 
2.2.1 Expression of PKC-ι in brain tissue. The relationship between absence of 
PKC-ι in normal brain tissue and its robust presence in either benign/malignant 
meningiomas or gliomas is shown in Fig. 8.  Western blots probed for PKC-ι in 12 
normal brain biopsies, 15 benign meningiomas and 6 malignant tumours revealed 
complete absence (N = 9) or very low detection (N = 3) of PKC-ι in normal brain tissue.  
By comparison, PKC-ι was very clearly evident in the majority of benign meningiomas 
(N = 14) but was only weakly present in one.  Similarly, PKC-ι was abundant in all 
malignant meningiomas (N = 3) and gliomas (N = 3).  PKC-ι immunoreactivity in 
glioma, benign and malignant menigiomas was 38-46 fold higher when compared to 
normal brain tissue.  PKC-βll did not show a pattern of expression specific to either 
normal brain tissue, or benign or malignant brain tumors (data not shown). 
30 
 
2.2.2 Over-expression of PKC-ι in glioma cells.  Actively proliferating cells (50% 
confluent) and 100% confluent serum starved cells were harvested and samples were 
prepared for cell cycle analysis or Western blotting.  T98G cells and U-138MG glioma 
cells that were 100% confluent had 94% and 74% of the cells in quiescence/Gap 1 
(G0/G1), respectively (Fig. 9A, C and Table 9).  In contrast, 64% of rapidly dividing 50% 
confluent T98G cells accumulated in G0/G1 phase and 54% of U-138MG glioma cells 
were in G0/G1 phase (Fig. 9B, D).  Western blotting for PKC-ι in these cell populations 
depicted robust quantities of PKC-ι in proliferating 50% confluent T98G and U138MG 
glioma cells. In contrast, 100% confluent cells had either 71% (T98G) or 47% (U-
138MG) less PKC-ι than 50% confluent cells (Fig. 9E, P<0.05).   
To determine a distribution pattern of different PKCs in glioma cells, we 
performed Western blots for PKC-α, PKC-β1, PKC-δ and PKC-ε in 100% confluent (plus 
serum starved) and proliferating cells.  PKC-β1 is known to play a role in angiogenesis 
and tumourigenesis [115].  Similarly, PKC-δ [116] and PKC-ε [117] are involved in 
glioma cell proliferation.  Invariant levels of PKC-α were observed between confluent 
versus proliferating cells (Fig. 9E).  Interestingly, Western blots for PKC-δ did not detect 
PKC-δ in T98G glioma cells and invariant levels were detected in U-138MG cells.  
Decreased levels of PKC-β1 (35% and 53% reduction) were seen in 100% confluent 
T98G and U-138MG cultures compared to rapidly proliferating 50% confluent cells, 
respectively (Fig. 9E). 
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Figure 8 PKC-iota is present in benign and malignant meningiomas, gliomas but not normal brain tissue. 
(A) Human autopsy-derived normal brain tissue (N1, frontal lobe; N2, cortex; N3 and N4, unspecified 
brain; N5, cortex; N6, cerebellum), benign tumour tissue (B1, B4, B7, B9 and B10, [WHO grade 1] 
meningothelial meningioma; B5 and B8, meningioma; B6, fibroblastic meningioma; B2, B3 and B11, 
fibrous meningioma [WHO grade 1], and malignant tumour tissue; M1 and M2, [WHO grade IV] 
glioblastoma multiforme; M3, right frontal lobe meningioma; M4, atypical meningioma [WHO grade II]; 
M5, Astrocytoma [WHO grade IV]; M6, anaplastic meningioma [WHO grade III]).Specimens were 
obtained from the Cooperative Human Tissue Network.  (B) Band density for PKC- ι was measured by 
densitometry.[118]
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Differences between PKC-β1 protein content in 100% confluent and 50% 
confluent rapidly proliferating cells were significant at (P < 0.05; n = 3) for both cell 
lines.  In contrast, PKC-ε was not detected in either T98G or U-138MG cells.  Western 
blots of PKC-α, PKC-β1, PKC-δ and PKC-ε, suggest that the presence or absence of 
these PKC isozymes may be cell type specific.  To insure that 48 h serum deprivation did 
not lead to cell death or alteration in intracellular cascades, we evaluated Caspase-7 
activation (Fig. 9E).  Results demonstrated that PKC-ι is highly overexpressed in glioma 
cells suggesting that PKC-ι may be required for cell cycle progression, proliferating and 
survival of glioma cells.  Although, PKC-βI and PKC-δ may have some role in glioma 
cell proliferation it is evident from the data that it is dependent on cell type.  For 
subsequent studies, we focused on the role of PKC-ι in glioblastoma. 
Table 9. Summary of 50% and 100% confluent cell cycle phases     
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Figure 9A-D Cell cycle analysis and expression of PKC-ι in T98G and U-138MG glioma cells.  FACS 
analysis of DNA content in 100% confluent (A) T98G or (C) U-138MG cells and 50% confluent (B) T98G 
or (D) U-138MG cells.  U-138 glioma cells are aneuploid; U-138MG DNA histograms are from one 
representative experiment and illustrate two cycling populations with a G0/G1 peak at 2 N (first red shaded 
peak) and another at 4 N (second yellow unshaded peak).  Total DNA content for G0/G1, DNA synthetic 
phase (S), gap 2 and mitosis (G2/M) was quantified by addition of each of the phases in both populations. 
Forty thousand events were collected per time point and treatment group.
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Figure 9E Cell cycle analysis and expression of PKC-ι in T98G and U-138MG glioma cells (E) Western 
blots of PKC-α, PKC-β1, PKC-δ, PKC-ε, PKC-ι, and Caspase 7 present in T98G or U138MG cells that 
were at different stages of confluence.  Band intensity of PKC-ι from the Western blots in T98G (F) and U-
138 MG (G) was quantified by densitometry.
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2.3 Discussion 
 Despite rigorous therapy, median survival is less than 1 year for patients with 
high-grade tumors.  While post-operative radiation therapy clearly delays tumor re-
growth and prolongs survival, total tumor control is rarely achieved.  Rapid glioma 
growth has been attributed to inherently high levels of PKCs.  PKC also appears to be 
involved in growth regulation of low-passage number human meningioma cells in vitro, 
as judged by decreased proliferation of cells following treatment with the PKC inhibitor, 
Staurosporine. 
In this study, we observed significant overexpression of PKC-ι in transformed 
phenotypes of human glioma and benign and malignant meningioma [118].  According to 
our understanding this is a first report on PKC-ι overexpression in glioma tissues.  
Notably, PKC-ι expression was also robust in glioma cell lines (T98G and U138MG).  In 
fact, when the cells were grown to 100% confluency and serum starved for 48h, 
expression of PKC-ι was significantly inhibited correlating with corresponding reduction 
in cell proliferation in comparison to actively proliferation (50% confluent) cells. 
Interestingly, such a reduction in cell proliferation did not drastically affect the 
expression of other PKC family members (PKC-α, δ, βI) suggesting that these isoforms 
may not be required for cell proliferation in these cell lines.  
Collectively, these data suggest a tissue specific role of different PKC family 
members.  Results also indicate that PKC-ι is highly activated and overexpressed in 
glioma cells and its presence may be essential for glioma cell proliferation and survival.  
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CHAPTER 3 
PKC-ι INDUCES CELL SURVIVAL IN GLIOMA CELLS 
3.1 Overview 
Glioblastoma multiforme is the most lethal form of all primary brain tumors with 
median survival time being less than a year.  Fast growth, aggressive proliferation and 
susceptibility to invasion and metastasis result in a poor prognosis in glioblastoma.  
Progress in glioblastoma therapy has remained stagnant despite rigorous therapeutic 
methods such as surgery, radiation and chemotherapy [18, 119].  Thus, there is a pressing 
need to identify novel molecular targets that might help improve survival of glioblastoma 
patients.    
PI(3)-kinase is frequently augmented in glioblastoma due to activating mutations 
or amplifications in EGFR (36% of the cases) or loss of function/deletion of PTEN (25% 
of the cases) [6, 17].  The atypical PKC family member, PKC-ι is a targeted mediator in 
the PI (3)-kinase signal transduction pathway [107].  The importance of PKC-ι as a 
signaling mediator is attributed to the fact that it can function as an oncogene [108, 109]. 
Bcl-2 (B cell lymphoma-2) family members are vital regulators of the 
mitochondrial cell death machinery and are comprised of 15 members [69].  Among the 
BH3 only protein, Bad lacks the hydrophobic C-terminal domain which prevents its 
direct mitochondrial interaction [120].  Upon external survival signals, Bad is 
37 
 
phosphorylated, deactivating and disrupting Bad/Bcl-XL dimerization [76].  Dissociated 
Bad further binds to 14-3-3 scaffold protein and is subsequently degraded [77].  Such 
imbalance in Bcl-2 family with more dependency on anti-apoptotic members is often 
observed to in cancer cells [78].   
We have previously reported that PKC-ι is highly expressed glioblastoma tissues 
[118]; however, little is understood about its role in glioma cell survival.  PKC-ι has been 
shown to inhibit the pro-apoptotic function of Bad in non-small cell lung cancer 
(NSCLC) cells when activated by nitrosoamine 4-(methylnitrosomaino)-1-(3-pyridyl)-
1butanone (NNK) [121].   
In this study we provide evidence that PKC-ι inhibited the pro-apoptotic function 
of Bad to promote glioma cell survival in T98G and U87MG glioma cells. The U87MG 
is classified as a grade IV astrocytoma and was isolated from highly malignant 
glioblastoma of a 44-year-old Caucasian female.  The cells have a hypodiploid 
chromosome count, display epithelial-like morphology and are tumorigenic in nude mice.  
The doubling time of U-87MG cells is approximately 32 h.   PI (3)-kinase inhibition, 
PDK1 inhibition and knockdown of PKC-ι activity upon siRNA treatment exhibited 
corresponding reduction in Bad phosphorylation hampering glioma cell survival.  Thus, 
our data suggests the presence of a novel PI (3)-kinase/PDK1/PKC-ι/Bad signaling 
cascade.  Targeting this pathway may be a possible glioblastoma targeted therapy.  
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3.2 Results 
3.2.1 PKC-ι, Bad and Bcl-XL expression in glioma cells.  In 50% confluent T98G 
cells (rapidly proliferating cells), there was increase in the expression of PKC-ι (90-fold, 
P=0.001) and Bcl-XL (66-fold, P=0.006) when compared with 100% confluent plus 
serum starved cells (contact inhibited) (Fig. 10).  Similarly, in U87MG cells, an increase 
in the levels of PKC-ι (50-fold, P=0.008) and Bcl-XL (20-fold, P=0.01) was observed in 
actively proliferating cells compared to serum starved cells (Fig. 10).  In contrast, the 
expression of Bad was enhanced in contact inhibited cells versus proliferating cells (44-
fold in T98G, P=0.004 and 52-fold in U87MG, P=0.002).  Caspase-3 was constitutively 
expressed in 50% confluent and 100% serum starved cells (Fig. 10).  Caspase-3 
expression levels were analyzed to ensure that the decrease in the expression of PKC-ι 
was not an outcome of cells undergoing apoptosis.  β-actin was used as the loading 
control. Therefore, our data suggests that presence of PKC-ι may be required for glioma 
cell survival and is inversely correlated with the regulation of mitochondrial Bad. 
3.2.2 PKC-ι co-localizes and directly associates with Bad.  The cellular 
distribution of Bad and Bcl-XL in T98G cells was determined by double 
immunofluorescence (IF).  Negative controls for FITC green, Texas red and their merged 
image exhibited minimal background immunofluorescence (IF) (Fig. 11A, top panel).  
PKC-ι had some nuclear staining but was stronger in the cytosolic region (FITC green) 
whereas Bad stained only in cytosolic fraction of the cells (Texas red) (Fig. 11A, bottom 
panel).  Merging of the two individual frames showed that PKC-ι predominantly co-
localized with Bad in the cytosolic region of the cells as displayed by yellow coloration 
39 
 
(Fig. 11A, bottom panel).  Small crescent shaped structures were observed near the 
perinuclear region of the cells, as indicated by the arrows.  The identity of this structure 
requires further investigation.  Subcellular fractionation of both T98G and U87MG cells 
showed that PKC-ι was present in both cytosolic as well as nuclear fractions (P <0.01 for 
T98G and U87MG).  Bad was present only in the cytosolic fraction of the cells 
(P=0.002).  β-actin was used as loading control.  Histone H1 was used as a purity control 
for nuclear fraction (Fig. 11B).   
To further demonstrate that PKC-ι directly associates with Bad, PKC-ι was 
immunoprecipitated.  In T98G cells, PKC-ι was constitutively expressed at all time points 
and directly associated with Bad.  The association, however, was transient as observed at 
T0, T6, T14, T16 hours (Fig. 11C).  Although PKC-ι associated with Bad in U87MG 
cells at most time points (T0-T36 hours), distinct variation in the Bad expression was 
observed (Fig. 11D).  We speculate that Bad may be involved in glioma cell cycle 
regulation however further investigation is required to confirm this hypothesis. 
                          
Figure 10 Expression profile of PKC-ι, Bad and Bcl-XL in T98G and U87MG cells.  PKC-ι, Bad, Bcl-XL 
and Caspase-3 expression levels in actively proliferating and contact inhibited plus serum starved T98G 
and U-87MG cells were determined by Western blot analysis.  β-actin indicates equal loading of the total 
lysate.  Western Blot is representative of N=3 independent experiments. 
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Figure 11A PKC-ι co-localizes and directly associates with Bad.  (A, top panel) displays IF controls 
incubated without primary antibody.  (A, bottom panel) represents the fluorescence from FITC green used 
to detect PKC-ι and the fluorescence from Texas Red to detect Bad, the merged image (yellow color) 
depicts co-localization of PKC-ι and Bad in the cytosol.  IF data represented is that of three repetitions.  
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Figure 11B-D PKC-ι co-localizes and directly associates with Bad  (B) Both T98G and U87MG cells were 
fractionated and Western blot analysis showed that PKC-ι is highly expressed in the cytosolic fraction and 
nuclear fraction of both cells, whereas Bad is expressed only in the cytosolic fraction.  β-actin was used as 
loading control.  Histone H1 was used as the purity control for the nuclear fraction.   (C-D), Whole cell 
extracts (1mg) from each time point (every 2h for T98G and 3h for U87MG) were IP with PKC-ι antibody.  
The 1st (-) contains whole cell extract plus rabbit IgG whole molecule (50μl of 1:1v/v) and the 2nd (-) 
contains whole cell extract plus rabbit IgG whole molecule (50μl) and normal rabbit IgG serum (5μg).  (C) 
PKC-ι transiently associates with Bad in T98G cells.  (D) PKC-ι in U87MG cells associates with Bad at 
most time points compared to T98G though its expression varies throughout the cell cycle (36h).  Data 
represents N=3 independent experiments.
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3.2.3 PKC-ι directly phosphorylates Bad at all three serine residues in-vitro.  
Since, our data showed that PKC-ι directly associates with Bad in both T98G and 
U87MG cells (Fig. 11C, D), we examined whether PKC-ι is a potential kinase to Bad in 
glioblastoma.  Significant increase in the levels of pBad at Ser-112, Ser-136 and Ser-155 
in co-IP (PKC-ι and Bad) samples compared to individual IP samples (Fig. 12A) suggests 
that Bad might be a direct downstream substrate to PKC-ι in T98G and U87MG cells.  
Further, when purified, active PKC-ι was incubated with IP Bad in an in-vitro kinase 
assay, active PKC-ι directly phosphorylated Bad at all three serine residues (Fig. 12B, 
P<0.05 for all the residues).  As reported by Jin et al. [121], our data also showed that 
active PKC-ι phosphorylated recombinant Bad at all three residues (P<0.01 for all 
residues) (Fig. 12C, upper panel).  In contrast, when, another atypical PKC, active PKC-ζ 
was incubated with recombinant Bad in an in-vitro kinase assay, PKC-ζ phosphorylated 
Bad at only Ser-112 residue (P=0.02) (Fig. 12C, upper panel) suggesting that it could 
also regulate Bad but would require other kinases in order to completely abrogate the pro-
apoptotic function of Bad.  To confirm that the activity of PKC-ζ was not compromised, 
PKC-ι and PKC-ζ were subjected to an in-vitro kinase activity assay using a common 
substrate, myelin basic protein (MBP).  Results showed that both, PKC-ι and PKC-ζ 
induced equivalent phosphorylation of MBP at T98, demonstrating equal activity 
(P<0.01) (Fig. 12C, bottom panel). 
Furthermore, when, Bad-associated Bcl-XL (bound Bcl-XL) was IP and 
incubated with purified, active PKC-ι (0.5µg) in an in-vitro kinase assay, we found lower 
amounts of bound Bcl-XL and increased levels of unbound Bcl-XL (Fig. 12D) in both 
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T98G (P=0.013)and U87MG cells (P=0.002).  Additionally, when, Bad associated 14-3-
3 (bound 14-3-3) was IP and incubated with purified, active PKC-ι (0.5µg), we found 
higher amounts of 14-3-3 in the samples incubated with PKC-ι, suggesting that increased 
phosphorylation of Bad (Fig. 12B) as well as Bad/Bcl-XL dissociation (Fig. 12D) led to 
increased Bad/14-3-3 dimerization (Fig. 12E) in both T98G(P=0.03) and U87MG cells 
(P=0.023).  14-3-3 is a proteosomal scaffold protein involved in Bad inactivation and 
degradation in the cytosolic fraction of the cells.  Thus dimerization of Bad with 14-3-3 
suggests that Bad will be subsequently sequestered by ubiquitin proteosomal pathway. 
These findings indicated that PKC-ι is a potential upstream kinase to Bad.  
3.2.4 Inhibition of PKC-ι activity leads to corresponding reduction in Bad 
phosphorylation.  Previous studies showed that pharmacological inhibition of PI (3)-
kinase blocked PKC-ι activity, suggesting that PI (3)-kinase is an upstream regulator of 
PKC-ι in glioblastoma [111].  Similarly, our results indicated that treatment of both T98G 
and U87MG cells with LY294002 (50µM) and Wortmannin (0.1µM) for 2 hours blocked 
PKC-ι activity in the form of diminished phosphorylation at T555 residue (53% with 
LY294002 and 68% with Wortmannin in T98G cells), (69% with LY294002 and 83% 
with Wortmannin in U87MG cells).  Marked reduction in the amount of Bad 
phosphorylation at Ser-112, Ser-136 and Ser-155 was also observed (Fig. 13A). 
PDK1 is a downstream mediator of PI (3)-kinase and previous studies have shown 
that PDK1 interacts and regulates the activity of atypical PKCs [106].  Thus, we 
investigated the effect of PDK1 knockdown on PKC-ι activity in glioma cells.  Our data 
showed that PDK1 knockdown inhibited the phosphorylation of PKC-ι at T555.  
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Subsequent reduction in the levels of Bad phosphorylation at Ser-112, Ser-136 and Ser-
155 was also observed (Fig. 13B).  Additionally, it has also been shown that in 
embryonic stem cells, where PDK1 is knocked out, expression of atypical PKC isoforms 
was significantly reduced [122].  Thus, we investigated the expression levels of PKC-ι 
and results showed marked reduction in expression of PKC-ι in PDK1 knockdown cells 
suggesting that PDK1 could also regulate PKC-ι expression, however further 
investigation may be required to explore this possibility. 
3.2.5 PKC-ι knockdown diminishes Bad phosphorylation; augments Bad/Bcl-XL 
association and inhibits Bad/14-3-3 dimerization.  When T98G and U87MG cells were 
treated with PKC-ι siRNA (100nM for 24h), Bad phosphorylation at Ser-112, Ser-136 
and Ser-155 was significantly inhibited in both the cell lines (Fig. 14A).  Furthermore, 
incubation with purified, active PKC-ι (0.5µg) restored the amount of Bad 
phosphorylation in PKC-ι siRNA treated cells (Fig. 14A).  Also, Bad-associated Bcl-XL 
(bound Bcl-Xl) increased (P=0.02) and Bad-associated 14-3-3 decreased (P=0.004) in 
PKC-ι siRNA treated cells (Fig. 14B).  In addition, when T98G and U87MG cells were 
treated with PKC-ζ siRNA, Bad phosphorylation at Ser-112 (P<0.05) was inhibited 
while phosphorylation at S136 and S155 remained constitutive (Fig. 14C).  These results 
indicated that PKC-ζ does not have the ability to completely inhibit Bad function. 
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Figure 12A-C PKC-ι induces direct phosphorylation of Bad.   
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Figure 12D-E PKC-ι induces direct phosphorylation of Bad.  The first negative control (-) contains whole 
cell extract plus rabbit IgG whole molecule (50μl of 1:1v/v) and the second negative control (-) contains 
whole cell extract plus rabbit IgG whole molecule (50μl) and normal rabbit IgG serum (5μg).  (A) IP Bad, 
IP PKC-ι and co-IP from T98G and U87MG cells were subjected to kinase activity assay.  Phosphorylation 
of Bad at Ser-112, Ser-136, Ser-155 and Pan Bad were quantified using Western blot analysis.  (B) IP Bad 
from both T98G and U87MG cells was incubated with active PKC-ι (0.5μg) in an in-vitro kinase activity 
assay as explained in “Methods”.  Western blot analysis was performed to determine phosphorylation of 
Bad at Ser112, Ser136 and S155 and Pan Bad.  (C, upper panel) Recombinant Bad (3.0µg) was incubated 
with purified, active PKC-ι and PKC-ζ (0.5µg) for 30 mins in an in-vitro kinase assay.  Western blot 
analysis was performed to determine pBad at Ser-112, Ser-136, Ser-155 and Pan Bad.  (C, lower panel) 
Recombinant MBP (3.0ug) was incubated with purified, active PKC-ι and PKC-ζ (0.5µg) for 30 mins in an 
in-vitro kinase assay followed by Western blot analysis to determine pMBP at Thr-98.  (D) Bad/Bcl-XL 
complex was IP from T98G and U87MG cells and subsequently incubated with purified active PKC-ι 
(0.5µg) for 30 mins in an in-vitro kinase activity assay.  The samples were centrifuged at 14000g for 
15mins.  Western blot analysis was performed on the resulting supernatant and the beads to determine the 
amount of bound Bcl-XL, unbound Bcl-XL and Pan Bad.  (E) Bad/14-3-3 complex was IP from both the 
cell lines and subsequently incubated with purified active PKC-ι (0.5µg) for 30 min in an in-vitro kinase 
activity assay.  The samples were centrifuged at 16000g for 15 min.  Western blot analysis was performed 
on the resulting supernatant and the beads to determine the amount of bound 14-3-3, Pan Bad.  Western 
blots are representative of three independent experiments.
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Figure 13 Effect of PI (3)-kinase inhibition and PDK1 knockdown in T98G and U87MG cells.  (A) Western 
blot analysis of T98G and U87MG cells for phospho-PKC-ι (T555), Pan PKC-ι, phospho-Bad (S112), 
(S136), (S155) and Pan Bad after individual treatment for 2 h with LY294002 (50µM) and Wortmannin 
(0.1µM).  (B) Both the cells were treated with PDK1 siRNA (100nM for 24h) followed by Western blot 
analysis to detect phospho-PKC-ι (Thr-555), phospho-Bad (Ser-112), (Ser-136), (Ser-155) and Pan PKC-ι 
and Bad.  Data is representative of three independent experiments.
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Figure 14 Knockdown of PKC-ι exhibits corresponding reduction in Bad phosphorylation and increase in 
Bad/Bcl-XL interaction. (A)  Both T98G and U87MG cells were treated with either control siRNA or PKC-
ι siRNA (100nM) for 24 hours.  Subsequently, Bad was IP and subjected to kinase activity assay followed 
by Western blot to detect pBad at Ser-112, Ser-136 and Ser-155 and Pan Bad. Another set of IP Bad was 
incubated with purified, active PKC-ι in an in-vitro kinase assay to detect its effect on the levels of pBad in 
PKC-ι siRNA treated samples.  (B) Bad was IP from both T98G and U87MG cells treated with either 
control or PKC-ι siRNA.  Bad associated Bcl-XL (bound Bcl-XL), Bad associated 14-3-3 (bound 14-3-3) 
and Pan Bad was analyzed using Bcl-XL, Pan 14-3-3 and Bad antibodies respectively.  (C) Both T98G and 
U87MG cells were treated with either control siRNA or PKC-ζ siRNA (100nM) for 24 hours.  
Subsequently, Bad was IP and subjected to kinase activity assay followed by Western blot to detect pBad at 
Ser-112, Ser-136 and Ser-155 and Pan Bad.  Data is representative of three independent experiments.
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3.3 Discussion 
We and others recognize PKC-ι as a potential molecular target because it is 
involved in cell proliferation, cell invasion, metastasis and chemoresistance in 
glioblastoma [111, 118].  In the current study, we observed that PKC-ι also mediates cell 
survival in glioblastoma.  In order to elucidate the signaling mechanism by which PKC-ι 
mediates its survival effect in glioblastoma, we investigated the role of Bcl-2 family 
protein, Bad and Bcl-XL [123].   
Our present data showed an inverse relation between the expression levels of 
PKC-ι and Bad in glioma cells, indicating a potential correlation between these two 
proteins.  In actively proliferating cells, PKC-ι is highly expressed, complementing our 
previous findings [118], whereas the levels of Bad were found to be diminished.  
However, under serum starved conditions, where the cells were quiescent [118], the 
expression of PKC-ι was significantly decreased while that of Bad was higher.  Recent 
findings of Fernando et.al have shown that overexpression of Bad in G1phase may not 
necessarily promote apoptosis, but it could inhibit cell proliferation [124].  Additionally, 
Bad has been shown to arrest G1-S progression of MCF7 breast cancer cells and this 
function depends on the phosphorylation state of Bad [124].  Thus, we hypothesized that, 
in glioma cells, PKC-ι might be regulating the activity of Bad by phosphorylation.  In 
order to test our hypothesis, we analyzed the association between PKC-ι and Bad in these 
cells.  Since, we observed transient association between PKC-ι and Bad, we speculated 
that there could be a cell cycle dependent involvement of the two proteins.  As predicted, 
there was transient but direct association of PKC-ι and Bad at different time points in the 
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cell cycle.  Further investigation may be required to determine the mechanism which 
induces such variable Bad expression in glioma cells.  Since, the function of Bad is 
dictated by its three phosphorylation sites [72] and as PKC-ι directly associated with Bad, 
we hypothesize that PKC-ι might be an upstream kinase to Bad in glioblastoma.  
Our results showed that endogenous PKC-ι not only co-localized and associated 
with Bad but also directly phosphorylated Bad at Ser-112, Ser-136 and Ser-155.  
Additionally, purified, active PKC-ι induced in-vitro phosphorylation of recombinant 
Bad, demonstrating that it is a potential Bad kinase.  This inactivation of Bad promoted 
its dissociation from Bcl-XL and inhibited its ability to quench the survival function of 
Bcl-XL.   
siRNA knockdown of PKC-ι reduced Bad phosphorylation, increased Bad/Bcl-
XL interaction and decreased Bad/14-3-3 dimerization.  Furthermore, active PKC-ι re-
stimulated the phosphorylation of Bad in these cells confirming that PKC-ι is a potent 
regulator of Bad function.  Such a cell survival mechanism has been previously shown in 
NSCLC; however, the activation of PKC-ι in these cells was NNK dependent [121].  In 
contrast, our results demonstrated that endogenous PKC-ι is highly activated in 
glioblastoma and it promotes survival of cells independent of any external stimulation.  
 PI (3)-kinase has been shown to induce activation of PDK-1 which subsequently 
phosphorylates and activates PKC-ι [106, 107, 111].  PI (3)-kinase and PDK1 inhibition 
not only blocked PKC-ι activity but also inhibited Bad phosphorylation.  This suggests 
that glioma cell survival occurs through a PI (3)-kinase signaling pathway.  Intriguingly, 
PDK1 knockdown also significantly inhibited the endogenous expression of PKC-ι in our 
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cells.  Previous studies have shown that in embryonic stem cells, where PDK1 was 
knocked out, there was marked reduction in the expression of atypical PKC isoforms 
(PKC-ζ, PRK1 and PRK2) [122], however, regulation of PKC-ι expression by PDK1 has 
never been shown before.  Understanding the mechanism by which PDK1 regulates 
PKC-ι expression will require further investigation.   
 
Figure 15 Graphical representation of PI (3)-kinase/PDK1/PKC-ι/BAD cell survival 
pathway 
Collectively, our data shows that PKC-ι promotes glioblastoma cell survival by 
regulating the pro-apoptotic function of Bad through PI (3)-kinase in absence of any 
external stimulation.  Thus, we show that PKC-ι expression may be used as a prognostic 
marker for the identification of glioblastoma patients that may benefit from anti-PKC-ι 
therapy for personalized medicine.   
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CHAPTER 4 
PKC-ι INDUCES CELL CYCLE PROGRESSION AND PROLIFERATION IN 
GLIOMA CELLS 
4.1. Overview 
Glioblastoma multiforme is a highly fatal primary brain tumor.  Its high 
propensity of invading the surrounding healthy brain tissue has prevented good prognosis 
in glioblastoma patients [12].  Rapid proliferation, fast infiltration and late diagnosis are 
hallmarks of glioblastoma that have rendered glioblastoma incurable.   
PKC is frequently observed to be altered and/or overexpressed in glioblastoma 
[103, 104].  Several studies have shown that PKC hyperactivity is correlated with the 
malignant growth rates in gliomas.   Frequent mutations/deletion in the PTEN gene or 
amplifications in EGFR occur in glioblastoma [9, 10] which constitutively augment PI 
(3)-kinase activity.  PKC-ι, an downstream mediator of PI (3)-kinase is highly expressed 
in glioma tissues [118]; however, its role in glioma cell cycle regulation and proliferation 
has not yet been completely defined.  Studies have also demonstrated a crosstalk between 
PKC-ι and Cdk7 in glioma, prostate cancer and neuroblastoma cells [125-127].  Cdk7, a 
member of the cyclin dependent protein kinase family, is a master cell cycle regulator 
[23] and mediates by phosphorylating and activating downstream cdks [24].  Among, all 
the cdks activated by Cdk7, cdk2 co-ordinates the transition from G1 phase to S phase of 
the cells [26].  In the current study we provide evidence that PKC-ι directly associated 
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and phosphorylated Cdk7 in a cell cycle dependent manner.  We also demonstrate that PI 
(3)-kinase and PDK1 inhibition suppressed PKC-ι activity and exhibited corresponding 
reduction in Cdk7 and cdk2 phosphorylation.  Direct PKC-ι knockdown inhibited Cdk7, 
cdk2 phosphorylation and abrogated glioma cell proliferation.  Thus, our data suggests 
that glioma cells may be proliferating through a novel PI (3)-kinase /PKC-ι/Cdk7 
signaling cascade that can be targeted for glioblastoma therapy.   
4.2 Results 
4.2.1 PKC-ι, Cdk7 and Cdk2 expression in glioma cells.  The expression of PKC-
ι, Cdk7 and cdk2 were higher in 50% confluent T98G cells (rapidly proliferating cells) 
than in 100% confluent plus serum starved cells (contact inhibited) (Fig. 16A).  A similar 
but less robust decrease in the levels of PKC-ι, Cdk7 and cdk2 in 100% confluent cells 
occurred in U87MG cells (Fig. 16A).  Constitutive expression of Caspase 3 showed that 
the decrease in the expression of PKC-ι was not due to cells undergoing apoptosis.  β-
actin was used as the loading control.  The cytoplasmic and nuclear expression of these 
proteins was higher in actively proliferating glioma cells (Fig. 16B).  In T98G cells, 
expression of PKC-ι, cdk2 was significantly depleted in 100% confluent plus serum 
starved cells (contact inhibited) versus proliferating cells.  Whereas, Cdk7 expression was 
reduced only by 2-fold in serum starved T98G cells.  The overall difference in the levels 
of PKC-ι and cdk2 was not especially robust in the sub-cellular fractions of U87MG cells 
(actively proliferating versus serum starved) in comparison to T98G cells (Fig. 16B).  
Thus, presence of PKC-ι in nucleus suggests a potential role of PKC-ι in glioma cell 
cycle progression and proliferation.
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4.2.2 PKC-ι regulates cell cycle progression and cell proliferation.  To determine 
cell cycle progression, we analyzed the DNA content of both T98G and U87MG cells at 
time points over a 36h period.  Initially the cells were populated (87% in T98G and 65% 
in U87MG) in the G1 phase.  There was progression into S phase from 18 until 24 h 
followed by increase in G2 phase by 30h, suggesting that the cells were progressing into 
mitosis (Fig. 17A, E). Western blot analysis of whole cell lysates at the indicated time 
points showed that expression of PKC-ι, Cdk7 and cdk2 was correlated with the cell 
cycle phases in both T98G (Fig. 17B) and U87MG cells (Fig. 17F).  When a majority of 
the cells were synchronized in the G1 phase, the levels of PKC-ι, Cdk7 and cdk2 was 
lower and expression of all three proteins increased as the cells progressed to S phase 
(Fig. 17B, F).  Such corresponding variation in the expression suggests an involvement of 
these proteins in T98G cell cycle progression.  Furthermore, PKC-ι was directly 
associated with Cdk7 and the levels of PKC-ι at the indicated time points coincided with 
the amount of pCdk7 and total Cdk7 (Fig. 17C, G).  Data from sub-cellular fractionation 
demonstrated that at the time points when the cells were transitioning from G1 the 
amount of PKC-ι and Cdk2 increased in the nuclear fraction (Fig. 17D, G).  The majority 
of Cdk7 was present in the nuclear fraction of both cell lines with slightly increased 
levels at later time points suggesting that the cells were proliferating.  Overall, these 
relationships were less evident in U87MG compared to T98G cells because of the innate 
asynchronous nature of U87MG cells.  A robust unidentified band was observed below 
the phosphorylated form of Cdk7 (Fig. 17C, G).  Determining the identity of this band 
requires further investigation.
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4.2.3 PKC-ι is an upstream Cdk7 kinase.  We recently demonstrated that PKC-ι is 
an in-vitro kinase to Cdk7 [33].  Here, we investigated whether PKC-ι/Cdk7 mediated 
signaling may also be occurring in glioma cells.  We measured a significant increase in 
pCdk7 at T170 in co-IP (PKC-ι and Cdk7) samples compared to individual IP samples 
(Fig. 18A).  In contrast, pcdk2 at T160 was observed only in IP Cdk7 samples and not in 
IP PKC-ι samples suggesting that PKC-ι may not be a cdk2 kinase.  Moreover, a three - 
fold increase in pcdk2 at T160 was observed in co-IP samples (PKC-ι and Cdk7) 
suggesting that the presence of PKC-ι probably increased Cdk7 activity which may have 
promoted a more robust downstream phosphorylation and activation of cdk2.  In addition, 
when purified, active PKC-ι was incubated with IP Cdk7 in an in-vitro kinase assay, 
direct phosphorylation of Cdk7 at T170 was observed (Fig. 18B, P<0.05).  These results 
suggest that PKC-ι is an upstream Cdk7 kinase and that glioma cells may be progressing 
through PKC-ι/Cdk7/cdk2 mediated signaling.
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Figure 16 Expression profile of PKC-ι, Cdk7 and Cdk2 in T98G and U87MG cells. (A) PKC-ι, Cdk7, cdk2 
and Caspase 3 expression levels in actively proliferating as well as contact inhibited plus serum starved 
T98G and U-87MG cells were determined by Western blot analysis.  β-actin was used as loading control.  
(B) Actively proliferating and contact inhibited plus serum starved T98G and U-87MG cells were 
fractionated into cytosolic and nuclear fraction.  Western blot analysis was performed to determine the 
expression of PKC-ι, Cdk7 and cdk2.  Histone H1 was used as the purity control for the nuclear fraction.  
Data is representative of N=3 independent experiments.
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Figure 17A-D. Cell cycle progression and PKC-ι, Cdk7, cdk2 protein expression in T98G and U87MG 
cells 
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Figure 17E-H. Cell cycle progression and PKC-ι, Cdk7, cdk2 protein expression in T98G and U87MG 
cells.  Briefly, T98G and U87MG cells were grown to 60-70% confluency followed by serum starvation for 
48 hours and subsequently serum stimulated for 36h.  Cells were harvested every 3h and prepared total 
Western blot.  (A, E) Total expression of PKC-ι, Cdk7 and cdk2 were analyzed by Western blotting of 
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whole cell lysates from the indicated time points.  β-actin was probed as a loading control.  (B, F) 
Duplicate time point samples were prepared for cell cycle analysis.  The histograms display the total DNA 
content in G1 phase (black bar), S phase (light grey bar) and G2 phase (Dark grey bar).  (C, G) PKC-ι was 
IP and its associated proteins were determined by Western blot analysis by probing for pCdk7 (T170), total 
Cdk7 and PKC-ι.  The first negative control (-) contains whole cell extract plus rabbit IgG whole molecule 
(50μl of 1:1v/v) and the second negative control (-) contains whole cell extract plus rabbit IgG whole 
molecule (50μl) and normal rabbit IgG serum (5μg).  (D, H) Sub-fractionated cell lysate (cytosolic and 
nuclear fraction) were subjected to Western blot analysis to determine the expression of PKC-ι, Cdk7 and 
cdk2 at each time point. 
 
4.2.4 PKC-ι knockdown leads to reduction in expression and activity of Cdk7 and 
cdk2.  To further prove the involvement of a PKC-ι/Cdk7/cdk2 proliferation pathway in 
T98G and U87MG cells, cells were treated with PKC-ι siRNA (100nM for 24h).  PKC-ι 
knockdown was determined by Western blot analysis of whole cell lysate (data not 
shown).  The Cdk7 phosphorylation at T170 and cdk2 phosphorylation at T160 was 
significantly inhibited in both cell lines treated with PKC-ι siRNA (Fig. 18A, P<0.005).  
In addition, a reduction in the expression of total Cdk7 and cdk2 was also seen.  This 
result supports our earlier data (Fig. 16, and 17) [34] that showed that expression of PKC-
ι, Cdk7 and cdk2 is crucial for glioma cell proliferation.  Furthermore, the reduction in 
PKC-ι induced Caspase-9 cleavage (Fig. 18B, P<0.05) implies that the cells are 
undergoing apoptosis via the intrinsic mitochondrial pathway.  PKC-ι knockdown also 
decreased the phosphorylation of the retinoblastoma (Rb), a tumor suppressor gene (Fig. 
87B, P<0.05) and increased the amount of p27 kip1 , a known Cdk inhibitor (Fig. 18B, 
P<0.05).  These results suggest that PKC-ι is involved in regulating Rb and p27kip1 which 
play essential roles in cell cycle machinery. 
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Figure 18 PKC-ι induces direct phosphorylation of Cdk7. (A, B) the first negative control (-) contains 
whole cell extract plus rabbit IgG whole molecule (50μl of 1:1v/v) and the second negative control (-) 
contains whole cell extract plus rabbit IgG whole molecule (50μl) and normal rabbit IgG serum (5μg). (A) 
IP Cdk7, IP PKC-ι and co-IP from T98G and U87MG cells were subjected to kinase activity assay.  
Phosphorylation of Cdk7 at Thr-170, pcdk2 at Thr-160 and Pan Cdk7 were quantified using Western blot 
analysis.  (B) IP Cdk7 from both T98G and U87MG cells was incubated with active PKC-ι (0.5μg) in an 
in-vitro kinase activity assay.  Western blot analysis was performed to determine phosphorylation of Cdk7 
at Thr-170, pcdk2 at Thr-160, PKC-ι and Pan Cdk7.  
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Figure 19 PKC-ι knockdown diminishes Cdk7 and cdk2 phosphorylation as well as cdk2 activity. (A) Both 
T98G and U87MG cells were treated with either control siRNA or PKC-ι siRNA (100nM) for 24 hours.  
Subsequently, Cdk7 was IP and subjected to kinase activity assay followed by Western blot to detect 
pCdk7 at T170, cdk2 atT160, total Cdk7 and total cdk2. (B) Whole cell lysate were from siRNA treated 
cells and subjected to Western blot analysis to detect Caspase 9, cleaved Caspase 9, pRb and p27kip1.
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4.2.5 Inhibition of PKC-ι activity precedes a reduction in Cdk7/cdk2 
phosphorylation.  Treatment with LY294002 (50µM) or Wortmannin (0.1µM) for 2 h 
blocked PKC-ι activity by diminishing its phosphorylation at the T555 residue in both 
T98G cells and U87MG cells (Fig. 20A, P<0.05).  Marked reduction in the amount of 
Cdk7 phosphorylation at T170 and cdk2 phosphorylation at T160 was also observed (Fig. 
20A, P<0.05), suggesting that PKC-ι regulates the expression of these proteins as 
previously observed (Fig. 17, 18 and 19).  β-actin was used as a loading control.  
Inhibition of PDK1 by siRNA (100nM) also diminished the endogenous amount of PKC-
ι which subsequently inhibited the activity of PKC-ι (pPKC-ι at T555) (Fig. 20B, 
P<0.05).  Correspondingly, a reduction in the levels of Cdk7 phosphorylation at T170 
and cdk2 at T160 was observed (Fig. 20B, P<0.05).  A modest reduction in the Cdk7 and 
cdk2 level was also observed further supporting our data shown in Fig. 16, 17 and 18.  
These results indicate that the PI (3)-kinase/PDK1 regulate the activity and expression of 
PKC-ι in these cells.
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Figure 20 Inhibition of PKC-ι activity precedes a reduction in Cdk7 and cdk2 phosphorylation in T98G 
and U87MG cells. (A) Western blot analysis of T98G and U87MG cells for phospho-PKC-ι (Thr-555), 
phospho-Cdk7 (Thr-170), phospho-cdk2 (Thr-160), Pan Cdk7, Pan cdk2 and PKC-ι following individual 
treatments for 2 h with LY294002 (50µM) and Wortmannin (0.1µM).  (B) Both cell lines were treated with 
PDK1 siRNA (100nM for 24h) followed by Western blot analysis to detect phospho-PKC-ι (Thr-555), total 
PKC-ι, phospho-Cdk7 (Thr-170), phospho-cdk2 (Thr-160), Pan Cdk7, Pan cdk2.  Data is representative of 
three independent experiments.
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4.3 Discussion 
PKC-ι, an atypical isoform of PKC family, is a key regulator of cell survival, 
invasion and chemoresistance in glioblastoma [3, 111, 112].  Previous data from our lab 
had demonstrated role of PKC-ι in glioma cell proliferation and involvement in malignant 
phenotype of glioblastoma. However, the mechanistic signaling remained unclear [118].   
PKC isotype profiling in previous studies demonstrated that PKC-ι was highly 
expressed in actively proliferating neuroblastoma, glioblastoma and prostate cells.  
However, under serum starved conditions, where the cells were quiescent, PKC-ι was 
significantly inhibited [118, 126, 127].  Our current studies also displayed similar 
overexpression of PKC-ι in proliferating glioma cells (T98G and U87MG) and reduced 
levels in serum starved cells.  Cdk7 and cdk2 level was also reduced in the serum starved 
conditions.  In addition, the analyses of the cytoplasmic and nuclear expression of these 
proteins (Fig. 16B) revealed that even though Cdk7 was constitutively present in both cell 
fractions, there was reduced cdk2 expression (in both T98G and U87MG cells) in the 
absence of PKC-ι, indicating that PKC-ι may be essential for regulating the expression of 
cdk2 (in presence of Cdk7) thereby triggering the cell proliferation.  Thus, the data 
suggest the importance of crosstalk between these proteins for glioma cell growth and 
proliferation.  This putative mechanism of regulation of cdk2 expression in glioma cells 
has never been reported before, however, further experimentation may be required to 
confirm this data. 
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Cdk7 regulates the eukaryotic cell cycle and is an in-vitro upstream kinase to 
cdk2 [87, 128].  Phosphorylation and activation of cdk2 controls the transition of cells 
from G1-S phase.  Our results showed that PKC-ι, Cdk7 and cdk2 levels increased 
continuously as cells progressed to S and subsequently G2 phase.  This suggests a 
potential correlation between these proteins in a cell cycle dependent manner.  Thus, we 
hypothesized that PKC-ι might be regulating the expression and activity of Cdk7, a cell 
cycle regulator.  To test this hypothesis, we analyzed the association between PKC-ι and 
Cdk7 in these cells.  The majority of PKC-ι associated with and phosphorylated Cdk7 at 
T18-T30 h suggesting that PKC-ι regulates cell cycle progression of glioma cells.  There 
was also a cell cycle dependent increase and translocation of PKC-ι, Cdk7 and cdk2 into 
the nucleus further supporting this hypothesis.  Although, an overall correlation was 
observed in both cell lines, U87MG did not show a similar pattern toT98G because 
U87MG cells are highly asynchronous in nature.  
Recent findings by Pillai et.al have shown that PKC-ι is an in-vitro upstream 
kinase to Cdk7 [127].  In the current studies, we found that PKC-ι not only associated 
with Cdk7 but also directly phosphorylated Cdk7 at T170 endogenously as well as 
exogenously suggesting that PKC-ι may also be an upstream Cdk7 kinase in 
glioblastoma.   
PKC-ι knockdown by siRNA treatment has been reported to inhibit glioma cell 
survival by suppressing the pro-apoptotic function of Bad [129].  Moreover, in this study, 
we observed that PKC-ι knockdown reduced Cdk7 and cdk2 phosphorylation suggesting 
that PKC-ι is not only required for glioma cell survival but may also be crucial for glioma 
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cell proliferation.  Such a mechanism has been previously shown in prostate cancer; 
however, PKC-ι did not directly associate with Cdk7 in DU-145 cells and only transiently 
associated with Cdk7 in RWPE-1 cells implying that PKC-ι may not be a direct upstream 
kinase to Cdk7 and that other kinases may be required to completely inhibit proliferation 
in these cells [126].  PKC-ι knockdown also regulated the expression of known cdk2 
substrates, Rb [96] and p27kip1 [130], implying that PKC-ι inhibition may lead to cell 
cycle arrest.  PKC-ι depletion also triggered Caspase- 9 cleavage suggesting induction of 
the intrinsic pathway mediated apoptosis in glioma cells, complementing our recently 
published data [129].  
PKC-ι silenced glioma cells as well as U.V. exposed glioma cells generated 
different distribution patterns of cell death. To our knowledge, these findings are the first 
evidence that PKC-ι inhibition generates early apoptosis and late apoptosis.  However, a 
conventional method of apoptosis induction, U.V. irradiation, produced mostly late 
apoptosis.  The CFSE/7-AAD analysis for the first time revealed the activity of the T98G 
cells that resisted cell death following PKC-ι silencing.  These resistant T98G cells were 
viable but experienced hampered cell division due to G2/M arrest.  A similar distribution 
pattern was also observed in the cell cycle analysis data wherein, a two-fold increase in 
G2/M cell population suggested that the cells might be going from G2/M arrest directly 
to apoptosis following RNA silencing.   
PI (3)-kinase, an upstream kinase of PDK-1 phosphorylates and activates atypical 
PKCs [106, 107, 111].  Pharmacological inhibition of PI (3)-kinase and PDK1, blocked 
PKC-ι activity and also inhibited Cdk7, cdk2 phosphorylation.  These results suggest that 
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glioma cell proliferation occured through a PI (3)-kinase mediated signaling pathway.  
Intriguingly, PDK1 knockdown also significantly inhibited the endogenous expression of 
PKC-ι and slightly that of Cdk7 and cdk2 in our cells.  Previous studies in embryonic 
cells showed that PDK1 knockout markedly reduced the expression of atypical PKC 
isoforms (PKC-ζ, PRK1 and PRK2) [106, 122]; however, regulation of PKC-ι by PDK1 
was never explored.  Thus, our findings are the first to postulate a role of PDK1 in the 
regulation of PKC-ι.  Further investigation is required to confirm this theory. 
   
 
Figure 21 Graphical representation of PI (3)-kinase/PKC-ι/Cdk7/cdk2 cell proliferation 
pathway
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In conclusion, these data suggest a role of PKC-ι in glioblastoma cell cycle 
progression and proliferation.  We show a novel mechanism indicating that PKC-ι is 
highly activated and overexpressed in glioblastoma.  PKC-ι induces uncontrolled glioma 
cell cycle progression and proliferation by modulating Cdk7/cdk2 activity in a PI (3)-
kinase dependent manner.   Furthermore, PKC-ι silencing studies demonstrated that 
glioma cells are highly resilient to conventional modalities suggesting that a 
combinatorial therapy may be required in the future to combat the apoptosis-resistant 
glioblastoma cells following PKC-ι downregulation. Thus, these results suggest that 
identification of PKC-ι and employing anti-PKC-ι therapy may help improve patient 
outcome in glioblastoma.   
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CHAPTER 5 
PKC-ι KNOCKDOWN INHIBITS CELL PROLIFERATION AND INDUCES 
APOPTOSIS IN GLIOMA CELLS 
5.1 Overview 
Glioblastoma is a deadly disease with a median survival time of 8-12months 
following prognosis.  Due to its extremely infiltrative and rapidly growing behavior, 
glioblastoma is a tremendously drug resistant type of cancer [18, 119].  Therefore, a 
better understanding of glioblastoma cells, proliferative and survival mechanisms and 
methods to achieve its inhibition are appropriate strategies to improve glioblastoma 
treatment. 
 Rapid glioma growth and survival has been attributed to inherently high levels of 
protein kinase Cs (PKC) [103].  In this study, we tested the effects of PKC-ι (an atypical 
PKC family member) silencing on the proliferative and survival mechanisms in 
glioblastoma.  The pathways involved in glioma cell survival and proliferation have been 
studied and detailed in the previous chapters (Chapter 3 and 4 respectively).  We 
observed that there was corresponding reduction in cell proliferation and induction of 
apoptosis with cell cycle arrest in glioma cells. 
Apoptosis or programmed cell death is broadly characterized by cellular 
morphological changes and energy dependent biochemical mechanism [131, 132].  
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Apoptosis is an essential component required for maintenance of cellular turnover, 
development and functioning of the immune system, aging and embryonic development 
[133].  Any alteration in this tightly regulated mechanism can lead to human conditions 
such as neurodegenerative disorders, autoimmune diseases and cancer [134].  Apoptosis 
plays a vital role in regulating the homeostasis to maintain various mechanisms in tissues 
[135].  
During early apoptosis, morphological changes in the cell occur, displaying cell 
shrinkage, chromatin condensation involving single cells or small clusters of cells, 
followed by extensive plasma membrane blebbing and budding [136, 137].  Such 
morphological observations were seen following PKC-ι silencing in this study.  There are 
two main mechanisms of apoptosis-extrinsic and intrinsic [138].  The molecular 
execution of apoptosis occurs via activation on cysteine dependent aspartate-specific 
proteases (Caspases) [139].  The intrinsic mode of apoptosis is dependent on a non-
receptor mediated mitochondrial-array of events involving the pro-apoptotic members of 
the Bcl-2 family [140].  The extrinsic apoptosis involves cell surface “death receptors” 
along with their ligands. 
Necrosis and autophagy are other types of cell death.  Necrosis is the premature 
death of cells or living tissue.  Necrosis is caused by external factors to the cell including 
infection, toxins or trauma.  It is in contrast to apoptosis which is a programmed cell 
death.  Cells that die due to necrosis do not send the same signals to the immune system 
as apoptosis preventing phagocytes from locating and engulfing the dead cells leading to 
dead cell build up.  Such a build up of necrotic tissue has to be removed surgically.   
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Autophagy or autophagocytosis also known as the type II programmed cell death, 
is a catabolic process involving the degradation of cell’s own components through the 
lysosomal system.  A tightly regulated process involved in cell growth, development and 
homeostasis, maintains a balance between synthesis, degradation and recycling of cellular 
products.  It is a main mechanism by which starved cells reallocates nutrient from 
unnecessary process to a more necessary one. 
In the previous study (Chapter 3), we observed a corresponding reduction in Bad 
(pro-apoptotic Bcl2- family member) phosphorylation following PKC-ι silencing.  Such 
activation of Bad promotes an apoptotic response that triggers energy dependent 
biochemical changes in the cells [132].  This causes loss of inner mitochondrial 
membrane that results in opening of the mitochondrial permeability transition (MPT) 
[141], loss of mitochondrial transmembrane potential [142] and release of cytochrome C 
and Smac/Diablo [143, 144].  This subsequently binds APAF1 [145] and pro-Caspase 9 
and activates Caspase 9 thereby triggering apoptosis by inhibiting the inhibitors of 
apoptosis proteins (IAPs) [146].  This further activates executioner Caspases (3, 6, 7) 
which degrade various nuclear and cytoplasmic proteins including PARP, cytokeratins 
and others [147].  Another marker apoptosis is reduction in Survivin protein which plays 
a vital role during the entire process of mitosis.  An additional apoptotic marker is the 
detection of Annexin V mediated binding of phosphatidylserine which is exposed on the 
outer leaflet of apoptotic cells [148]. 
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5.2 Results 
5.2.1 PKC-ι knockdown reduces cell viability.  A dose response treatment of 
T98G cells with PKC-ι siRNA (25nM-125nM) over a 48 h time course was performed 
using MTS assay according to manufacturer’s instructions.  The absorbance data showed 
that PKC-ι siRNA significantly inhibited cell proliferation of T98G cells with 71.4% at 
24 h using a concentration of 100nM (P<0.001) (Fig. 22A).  We also determined the 
amount of cell viability in PKC-ι siRNA treated cells when compared to control cells.  
The average percentage of cell death was analyzed by Trypan blue exclusion assay.  
Results showed that PKC-ι siRNA (100nM) significantly inhibited cell viability of T98G 
(74% at 24h and 63% at 48h) and U87MG (85% at 24h and 72% at 48h) cells (Fig. 22B).  
These results suggest that PKC-ι silencing inhibited cell viability and proliferation rate of 
glioma cells.   
5.2.2 PKC-ι siRNA treatment specifically inhibits PKC-ι expression.  Western blot 
analysis illustrated that PKC-ι siRNA treated cells showed diminished expression of 
PKC-ι in T98G (77% at 24h and 61% at 48h) and U87MG (80% at 24h and 69% at 48h) 
cells compared to control siRNA treated cells (Fig. 23).  The silencing effect of PKC-ι 
was highly specific as no cross reactivity was observed when the membrane was 
immunoblotted for PKC-ζ (Fig. 23).  This suggests that the siRNA sequence is highly 
specific for PKC-ι and hence is potent in silencing the translation of PKC-ι in T98G and 
U87MG cells.  
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5.2.3 PKC-ι knockdown potently inhibits cell proliferation in glioma cells.  The 
distribution pattern of cell cycle phases following PKC-ι silencing in T98G cells 
demonstrated significant changes (Fig. 24B, D).  A significant (2-fold) increase in G2 
phase was seen following 48h-post siRNA transfection in comparison to control cells 
(Fig. 24C, D).  In addition, a significant increase in cell death was observed suggesting 
that the cells might be going from G2/M arrest directly into apoptosis after 48h PKC-ι 
siRNA treatment (Fig. 24D).  
Additionally, it was important to gain further understanding of the extent to which 
PKC-ι modulates the mitotic phase of the cell cycle (Fig. 24E).  Therefore, the 
proliferation rate was measured by the CFSE dilution assay (i.e., a shift demonstrating a 
decrease in fluorescence intensity).  By 48h, the proliferation rates for the no treatment 
group and control siRNA group (also fixed CFSE positive control) were significantly 
greater than the proliferation rate for PKC-ι silenced T98G cells (Fig. 24F, G).  By 
simultaneously measuring the actively proliferating cells and nonviable cells, it was 
confirmed that many of the cells were going from G2/M arrest directly into apoptosis 
after PKC-ι inhibition (Fig. 24E, G).  
5.2.4 PKC-ι silencing induces cellular changes indicating apoptosis in glioma 
cells.  PKC-ι siRNA (100nM) treated cells displayed distinct morphological changes such 
as loss of cell membrane symmetry, cell shrinkage, as well as detachment of cells was 
observed indicating that cells might be undergoing apoptosis (Fig. 25A).  Several 
biochemical changes were also observed following siRNA treatment upon Western blot 
analysis on whole cell lysates.  Primary marker of the apoptosis process is activation of 
effector Caspases.  Current data showed that there was robust decrease in the amount of 
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pro-Caspase 3 upon PKC-ι siRNA treatment.  A downstream effect of the Caspase 
activation is release of cytochrome C from the mitochondria which was notably seen 
following PKC-ι siRNA treatment in both cell lines.  Expression of Survivin was also 
observed to be significantly inhibited in PKC-ι siRNA treated cells (Fig. 25B).  These 
data suggest that PKC-ι silencing led to apoptosis induction in glioma cells. 
        
Figure 22 PKC-ι knockdown reduces cell viability (A) T98G cells were treated with increasing 
concentration of either control siRNA or PKC-ι siRNA (25nM-125nM) for 24 and 48 hours.  At each time 
point, cell proliferation was detected using MTS assay.  Data represents N=3 independent studies.  (B) 
Both T98G and U87MG cells were treated either with control siRNA or PKC-ι siRNA (100nM) for 24-48 
h.  At the indicated time points, cell viability was quantified using Trypan blue exclusion assay.  Data 
represents three independent studies.  
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Figure 23 PKC-ι expression is highly diminished upon siRNA treatment.  (A)Western blot analysis in total 
cell extracts (30µg) was performed to determine the expression of PKC-ι and PKC-ζ.  β-actin displays 
equal loading of protein.  (B) Western blots represent three independent studies. PKC-ι immunoreactivity 
absorbance is shown by densitometry.
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Figure 24A-D PKC-ι inhibits cell proliferation in glioma cells  The distribution pattern of cell cycle phases 
in PKC-ι knockdown cells is compared with control cells (A) 24h-Control siRNA treated cells, (B) 24h-
PKC-ι siRNA treated cells, (C) 48h-control siRNA treated cells, (D) 48h-PKC-ι siRNA treated cells.
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Figure 24E-G PKC-ι inhibits cell proliferation in glioma cells. (E) Proliferation inhibition after PKC-ι 
silencing in comparison to control cells was assessed by the CFSE dilution assay with live gate analysis.  
(F) PKC-ι silenced cells and control cells were analyzed by 7-AAD staining to determine the average 
percentage of dead cells. (G) Average percentage of proliferating cells was measured by CFSE dilution 
(examined from the Live Gate) from PKC-ι knockdown and control cells.  The experiment was repeated 
twice with a total N=4.  *p<0.05, student’s t-test for specified treatment groups,  **p<0.05, student’s t-test 
for all treatment groups.
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5.2.5 PKC-ι silencing induces apoptosis in T98G glioma cells.  PKC-ι 
downregulation along with the subsequent inhibition of cell proliferation and increase in 
cell death, lead us to examine the specific assessment of cell death rates after siRNA 
transfection in T98G cells.  The average death rate obtained with the Trypan blue method 
demonstrated similar cell death rates as the Annexin V-FITC/PI assay for each treatment 
group under investigation (Fig. 26A).  PKC-ι siRNA treatment or both U.V. exposures 
generated significantly higher percentages of overall cell death in comparison to the no 
treatment group and the control siRNA group (Fig. 26A).  Nevertheless, the 25 min U.V. 
exposure produced significantly more overall cell death than any of the treatment groups 
(Fig. 26A).  Further analysis of Annexin V-FITC/PI data provided an additional 
perspective on the change in the cell death distribution patterns following the 
downregulation of PKC-ι in T98G cells (Fig. 26B).  The T98G cells were so resilient that 
U.V. irradiation for less than 20 min did not induce much cell death (data not shown).  
PKC-ι siRNA exposure or 25 min exposure to U.V. irradiation induced a 34% overall 
apoptotic rate which was significantly more than that observed in untreated cells or the 
control siRNA treated cells (Table 10).  Notably, it was found that 20 min was the 
threshold for the T98G cell’s capacity to hold its membrane integrity intact after direct, 
continuous exposure to U.V. irradiation.  Both U.V. exposure times induced significantly 
more late apoptosis than PKC-ι siRNA treated T98G cells where as PKC-ι silencing 
produced the most significant level of early apoptosis in comparison to all treatments 
(Fig. 26B and Table 10).  Furthermore, both exposure times to U.V. irradiation led to 
significantly more necrotic T98G cells than any other treatments (Fig. 26B and Table 10).
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Figure 25 PKC-ι knockdown induces morphological and biochemical changes. (A) Brightfield pictures 
following PKC-ι siRNA and control siRNA treatment depicting morphological changes in T98G and 
U87MG cells (B) Control siRNA or PKC-ι siRNA (100nM for 24 h and 48 h) treated T98G and U87MG 
cells were harvested and total protein (100µg) was analyzed by Western blot to detect several biochemical 
changes such as PARP, PARP cleavage, Caspase 3, cytochrome C and Survivin.  β-actin displays equal 
protein loading.  Data represents N=3 independent experiments.
80 
 
 
 
Figure 26 PKC-ι silencing induces apoptosis in T98G glioma cells (A) Cell death induced by PKC-ι 
inhibition was detected using the Trypan blue exclusion method (left panel) and the Annexin V-FITC/PI 
assay (right panel).  U.V. treatment was used as positive control for apoptosis detection.  (B) The 
distribution pattern on cell death by PKC-ι knockdown was compared with control siRNA treated and 
untreated cells.  U.V. treatment was used as positive control for apoptosis detection.  Representative Dot 
plots of the Annexin V/PI analysis for overall apoptotic rate, late apoptotic rate, early apoptotic rate and 
necrotic rate.  Experiments were repeated four times with a total N=8 for all treatment groups. U.V. 
treatment groups had N= 3-5. The significance is explained in Table I for this data.
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Table 10 Distribution pattern of cell death after PKC-ι silencing  
 
*p<0.05, Student’s t-test compared to untreated groups; **p<0.05, Student’s t-test for all control groups; 
***p<0.05, Student’s t-test for all treatment groups except for alternate U.V treatment group; ****p<0.05, 
Student’s t-test for all treatment groups. 
5.3 Discussion 
PKC-ι, an atypical PKC isoform is known to be hyperactivated and overexpressed 
in glioblastoma and our previous data has shown that PKC-ι is required for glioma cell 
proliferation and survival [118, 129].  However, the effects of PKC-ι inhibition in glioma 
cells have remained unclear. 
In this study, data showed that PKC-ι expression was significantly downregulated 
following siRNA transfection in both T98G and U87MG cells.  PKC-knockdown not 
only inhibited the endogenous expression of PKC-ι but also triggered alterations in the 
cells indicating apoptosis. Several morphological changes and biochemical changes 
confirmed the activation of intrinsic mode of apoptosis in both cell lines.
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Additionally, PKC-ι silenced glioma cells as well as U.V. exposed glioma cells 
generated different distribution patterns of cell death. To our knowledge, these findings 
are the first evidence that PKC-ι inhibition generates early apoptosis and late apoptosis.  
However, a conventional method of apoptosis induction, U.V. irradiation, produced 
mostly late apoptosis. The CFSE/7-AAD analysis for the first time revealed the activity 
of the T98G cells that resisted cell death following PKC-ι silencing.  These resistant 
T98G cells were viable but experienced hampered cell division which reflected G2/M 
arrest.   
A similar distribution pattern was also observed in the cell cycle analysis data 
wherein, a two-fold increase in G2/M cell population suggested that the cells might be 
going from G2/M arrest directly to apoptosis following siRNA silencing.  Such effects 
were observed in cells grown in tissue culture (also demonstrated by Baldwin et.al) [149], 
contradicting the observations in other cancer models where such an effect was seen only 
in anchorage independent cells signifying a tissue specific role of PKC-ι [1, 150].  
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CHAPTER 6 
BROAD CONCLUSION AND FUTURE DIRECTIONS 
6.1 Conclusion 
 This research demonstrated that PKC-ι is hyper activated and over-expressed in 
glioma cells.  PKC-ι expression is also significantly robust in transformed phenotypes of 
human glioma and benign and malignant meningioma.  This study showed that PKC-ι is 
multifunctional and its expression in concordant with malignant growth rates in gliomas.   
 Our data showed that PKC-ι is an in-vitro kinase to Bad, a pro-apoptotic molecule 
of Bcl-2 family as well as Cdk7, a master cell cycle regulator.  In glioma cells, PKC-ι 
directly associated and inactivated Bad function to promote uncontrolled cell survival via 
Bad/Bcl-XL dissociation.  PKC-ι also triggered cell cycle progression and cell 
proliferation in glioma cells by regulating the activity of Cdk7.  Results also indicated 
that PKC-ι is activated by PI (3)-kinase and PDK1 mediated signaling.  PI (3)-kinase 
downregulation and PDK1 knockdown abrogated PKC-ι activity resulting in inhibition of 
PKC-ι downstream substrate function.  Additionally, direct PKC-ι silencing inhibited Bad 
phosphorylation subsequently inducing apoptosis in glioma cells.  This suggests that 
apoptosis occurs via Bad mediated mitochondrial pathway.  Furthermore, PKC-ι 
downregulation inhibited Cdk7 activity and subsequently reduced cdk2 function.  
Silencing the PKC-ι/Cdk7/cdk2 pathway inhibited cell proliferation, induced G2/M cell 
cycle arrest as well as triggered intrinsic mode of apoptosis in glioma cells. 
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 In conclusion, these results show that PKC-ι executes cell survival, cell cycle 
progression and cell proliferation mechanisms in glioblastoma.  Collectively, this study 
suggests that PKC-ι is a potential predictive biomarker for the identification of 
glioblastoma patients that may benefit from anti-PKC-ι therapy for personalized medicine 
to improve the prognosis of glioblastoma patients. 
 
 
Figure 27.Graphical representation of PKC-ι signaling in glioblastoma
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6.2 Future directions 
This study has paved the way for future studies in glioblastoma as well as other 
cancer models. 
1. Other Bcl-2 family proteins may also be involved in PKC-ι mediated 
survival mechanism.  Studying these possible pathways may help 
identifying new therapeutic targets in glioblastoma. 
2. Using novel chemotherapeutic agents to inhibit the PI (3)-kinase/PKC-
ι/Bad cell survival cascade may be strong strategy to fight glioblastoma. 
3. Verify the effect of PKC-ι overexpression of cell cycle progression and 
proliferation in glioblastoma. 
4. Target PI (3)-kinase/PKC-ι/Cdk7 cdk2 pathway to prevent uncontrolled 
cell proliferation in glioblastoma. 
5. Identify and investigate whether PKC-ι may be a potential biomarker in 
other cancer models 
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CHAPTER 7 
MATERIALS AND METHODS 
7.1 Materials.  
 Recombinant active PKC-ι (14-505), PKC-ζ (14-525), soluble Bad (14-357) and 
primary antibodies for PKC-ζ (07-264), myelin basic protein (MBP, 05-675), phospho 
MBP (05-429) and 14-3-3 (AB9748) were purchased from Millipore (Temecula, CA).  
PKC-ι primary antibody was purchased from BD Biosciences (San Jose, CA).  Bad (sc-
7869), PKC-ι (sc-727), phospho Bad Ser-112 (sc-7998), phospho Bad Ser-136 (, phospho 
Bad Ser-155 (sc-101641), histone H1 (sc-8030) and β-actin (sc-1616) primary antibodies 
were purchased from SantaCruz Biotechnology (SantaCruz, CA).  Bad (9292), Bcl-XL 
(2764) were purchased from Cell Signaling.  Cdk7 (sc-529), cdk2 (sc-748), pRb, p21 (sc-
187), p27 (sc-527), histone H1 (sc-8030) and β-actin (sc-1616) primary antibodies were 
purchased from SantaCruz Biotechnology (SantaCruz, CA).  pCdk7 primary antibody 
was purchased from Abcam.  pcdk2 (2561), Caspase 9 (9502) and cleaved Caspase 9 
(9501), Poly adipose ribose polymerase (PARP, 9542), Caspase-3 (9662), cytochrome C 
(4272) and survivin primary antibodies were purchased from Cell Signaling Technology 
(Danvers, MA).  Horseradish peroxidase (HRP) conjugated bovine anti-goat IgG (sc-
2350) and HRP Goat anti-rabbit IgG (sc-2004), as well as secondary antibodies were 
purchased from SantaCruz Biotechnology (SantaCruz, CA).  Goat anti-mouse IgG, HRP 
conjugate (12-349) and normal rabbit IgG (12-370) were purchased from Millipore 
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(Temecule, CA).  Wortmannin (W1628), LY294002 (L9908) and anti-rabbit IgG (whole 
molecule)-conjugated with agarose beads (1:1 v/v) (A8914) were purchased from Sigma 
Aldrich (St. Louis, MO).  PKC-ι silencing RNA (siRNA) (sc-44320), PKC-ζ siRNA (sc-
29451) and PDK1 siRNA (sc-36203) was purchased from SantaCruz Biotechnology 
(SantaCruz, CA).  Nuclear and cytoplasmic kit (78833) was purchased from Pierce 
(Rockford, MO), Apodetect Annexin V-FITC kit (33-1200) and Vybrant CFDA SE Cell 
kit (V12883) were bought from Invitrogen (Grand Island, NY) 
Other chemicals such as HEPES (BP310-500), tris-glycine 10X (BP1306), SDS 
(BP166-500), tris-base (BP152-500), glycerol (BP229), triton x100 (BP151-500), 
methanol (A407), hydrochloric acid (A144) were purchased from Fisher Scientific, 
Norcross, GA. Ethylene glycol bis(β-aminoethyl ether)-N,N,N’,N’, -tetraacetic acid 
EGTA (E4378), sodium floride (S6521), sodium orthovanadate (S6508), PMSF (P7626), 
leupeptin (62070), aprotinin (A6279) were purchased from Sigma Aldirch, St. Louis MO. 
Protein assay dye (500-0006), EDTA (161-0729), tris-buffered saline 10X (170-6435) 
were purchased from Bio-Rad, Richmond, CA. Bovine serum albumin (BSA) (23209) 
and SuperSignal West Pico chemiluminescent substrate (34080) were purchased from 
Pierce, Rockford, IL.  
7.2 Cell Culture.  
All cell lines were cultured as a monolayer in 75cm2 flasks containing Eagles 
Minimum Essential Medium (MEM), 10% fetal bovine serum (FBS) and antibiotics 
(penicillin 10 U/ml and streptomycin 10µg/ml) at 37˚C in a humidified atmosphere 
containing 5% CO2.
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7.3 Cell fractionation and Western blotting. 
Cells (1 x 106) were placed on ice to terminate the incubation. Cell extracts were 
prepared by washing twice with 10 ml of ice cold 1X Dulbecco’s phosphate buffered 
saline (DPBS).  Monolayers were scraped at 4°C, resuspended and sonicated in 
homogenization buffer (50 mM HEPES, p.H. 7.5), 150 mM NaCl, 0.5% triton-X100, 
1mM EDTA, and 2mM EGTA, 0.1 mM sodium orthovanadate, 1mM NaF, 2mM PMSF, 
1mM DTT, 0.15 U/ml aprotinin. Cell suspensions were centrifuged at 16000g for 30 min 
to obtain cell extracts.  Protein content was measured according to Bradford using bovine 
serum albumin (BSA)as standard. [151].  Protein samples were separated by 12% on 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (1.5mm thick 
gel) [152] using Protean II xi 16cm gel loading system (BioRad) and electrophoresed at 
160volts and subsequently transblotted [153] by electroblotting with transfer buffer 100 
ml of 10 x tris glycine (0.25 M tris and 1.92 M glycine) and 20% methanol in 1 L of 
distilled water and electroblotted for one hour at 24 volts.  For Western blot analysis, 
each blot was blocked for 1 hour with 5% (w/v) fat-free dry milk in tris-buffered saline 
with 0.05% tween-20 (TBST) solutions at room temperature.  Protein bands were probed 
with primary antibody in 5% milk in blocking buffer at 4°C overnight.  The primary 
antibodies dilutions were 1:1000-1:5000. Membranes were subsequently washed three 
times for 15 minutes with TBST.  Secondary antibodies such as horseradish-peroxidase-
conjugate anti-mouse, anti-rabbit or anti-goat were diluted 1:1000 in 5% milk TBST.  
The membranes were incubated with secondary antibody (1:5000) at room temperature 
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for 1 hour.  Immunoreactive bands were visualized with SuperSignal West Pico 
Chemiluminescent substrate. 
7.4 Cell-cycle time course and immunoprecipitation. 
Cells were cultured as monolayers in 150 mm tissue culture plates until 50-60% 
confluent, followed by serum starvation for 48h.  Subsequently, starvation media was 
removed and complete media was added to each plate to allow cells to complete the cell 
cycle.  T98G were harvested every 2h and U87MG were harvested every 3h by placing 
the plates containing cells on ice and washing twice with ice cold 1x DPBS.  Cells were 
subsequently scraped and re-suspended in homogenization buffer.  Protein content was 
measured according to Bradford using BSA as standard.  Cell lysates (1 mg) were pre-
cleared for 30 min at 4°C with anti-rabbit IgG-agarose beads (1:1 v/v, 10μl) and 
incubated with 5μg of either anti-PKC-ι, anti-Bad rabbit polyclonal antibody or both, 
overnight at 4°C and additionally with anti-rabbit IgG-agarose beads (1:1 v/v, 50 μl).  The 
protein associations were subsequently determined by Western blot analysis. 
7.5 Brain Tissue. 
Human autopsy-derived brain tissue and meninigiomas were obtained from the 
Cooperative Human Tissue Network (Southern Division) at the University of Alabama 
(Birmingham, AL, USA). Tissue specimens were obtained from both males and females 
of varying ages (23 - 80 years of age).  Normal brain tissue included specimens from the 
frontal lobe, brain cortex, cerebellum, hippocampus, pons, corpus collosum and basal 
ganglia.  Tumors labeled ‘benign’ were meningiomas. Malignant tumors were either 
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meningiomas or gliomas. The brain tissues were stored in -80°C freezer. Tissue samples 
were lysed by a sonicator and processed by a lysis buffer and the lysates (50μg) were 
subjected to gel electrophoresis and Western blotting was performed using antibodies 
against PKC-ι and β-actin. 
7.6 Cell-cycle analysis. 
T98G and U87MG cells were cultured as monolayers in 150 mm tissue culture 
plates until 50-60% confluent, followed by serum starvation for 48h.  Subsequently, 
complete media was added to each plate allowing the cells to complete the cell cycle.  
Cells were harvested every 3h and fixed in ice-cold 70% ethanol at 4ºC overnight.  Fixed 
cells were washed with 1x DPBS and re-suspended in PBTB (PBS, 0.2% triton X-100, 
1% bovine serum albumin) with final concentration of 1x 106 cells/ ml.  Subsequently, 
50µl RNase (1µg/µl) was added and the nuclei were stained with PI (1µg/µl).  The 
distributions of nuclei were quantified using FAC STAR plus flow cytometry (Becton 
Dickinson, San Jose, CA) and ModFitLT Cell cycle analysis program, version 2.0 (Verity 
Software House, Topsham, ME). 
7.7 Immunofluorescence. 
Approximately 1 x 106 cells were plated and grown in 2-well culture slides 
(Collagen type I coated).  Twenty-four hours post-plating, cells were washed with cold 
1x DPBS and fixed with 1:1 concentration of methanol and acetone for 5 min at - 20°C.  
Cells were incubated with 8% normal goat serum blocking buffer for 45 min followed by 
incubation with anti-mouse antibody against PKC-ι for 90 min and incubated with anti-
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mouse secondary antibody for 30 min followed by staining with fluorescein 
isothiocyanate (FITC) dye diluted in its blocking buffer (Vector Laboratories) for 30 min.  
Cells were washed 3 times with 1x DPBS followed by blocking with 8% normal horse 
serum for 45 min.  Subsequently, cells were incubated with primary anti-rabbit antibody 
against Bad for 90 min and then incubated with anti-rabbit secondary antibody for 30 min 
followed by staining with Texas red diluted in its blocking buffer.  Cells were washed 3 
times with 1x DPBS and cell nuclei were visualized with mounting medium containing 
DAPI (4', 6-diamidino-2-phenylindole) which stains blue.  Cells were observed with a 
Nikon Eclipse TE2000-U microscope.  Pictures were captured in NIS-Elements F 
Version 2.10.  To illustrate subcellular regions of protein co-localization, individual red 
and green-stained images derived from the same field were merged in Image-Pro Express 
Version 5.1.  
7.8 Subcellular fractionation. 
Cells were washed twice with cold PBS and resuspended in hypotonic Buffer A 
[50 mM HEPES, pH 7.4), 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 
1 mM PMSF, 2.5 μg/m leupeptin, 0.15 U/ml aprotinin.  The lysates were centrifuged at 
4000 g for 30 min at 4°C and the supernatant (cytoplasmic proteins) was collected.  The 
pelleted nuclei were extracted with Buffer A containing 400 mM KCl and 0.5% triton X-
100.  After centrifugation at 14000 g for 30 min at 4°C, the supernatant containing 
nuclear extracts was collected. The expression of PKC-ι, Bad, Cdk7 and cdk2, histone H1 
and β-actin were determined by Western blot analysis.
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7.9 PKC activity assay. 
PKC activity assay was performed by suspending recombinant active PKC-ι, 
recombinant active PKC-ζ (0.5μg each) individually in 200μl of PKC kinase buffer [154] 
to test the ability of each PKC to phosphorylate recombinant as well as endogenously 
immunoprecipitated Bad and recombinant MBP.  The PKC kinase buffer consisted of 
20mM Tris- HCl (pH 7.5), 6mM magnesium acetate, phosphatidylserine (5μg) and 
adenosine triphosphate ATP (0.96μg).  The reaction was terminated after incubation for 
30 min at 30°C by addition of sample loading buffer and by placing the samples on ice.  
Proteins were subsequently separated by SDS-PAGE and analyzed by Western blot 
analysis using PKC-ι, PKC-ζ, Bad, pBad at Ser-112, Ser-136 and Ser-155, MBP, pMBP 
at T-98 as well as Cdk7 and phospho-Cdk7 (T170).   
7.10 Inhibition of gene expression. 
PKC-ι siRNA was a pool of three combined RNA sequences for targeting PKC-ι.  
Their mRNA sequences were  
663: 5’-CAAGCCAAGCGUUUCAACA-3’  
    5’-UGUUGAAACGCUUGGCUUG-3’  
729: 5’-GGAACGAUUGGGUUGUCAU-3’  
     5’-AUGACAACCCAAUCGUUCC-3’ 
2137: 5’-CCCAAUAUCUUCUCUUGUA-3’  
       5’-UACAAGAGAAGAUAUUGGG-3’
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and control siRNA contained a scrambled sequence which does not lead to specific 
degradation of any known cellular mRNA and whose sequence is proprietary information 
of Santa Cruz Biotechnology.   
Approximately, 1x106 cells were grown as monolayers in 100mm tissue culture 
plates. Twenty-four hour post-plating, cells were transfected with either PKC-ι or control 
siRNA (100nM) using lipofectamine medium.  Cells were harvested after 24 h treatment 
and Bad was IP (1mg) followed by kinase activity assay and Western blotted to 
investigate to amount of Bad phosphorylation and Bcl-XL expression in both T98G and 
U87MG cells.  Another set of IP Bad was incubated with purified, active PKC-ι in in-
vitro kinase assay to examine the level of Bad phosphorylation. 
siRNA transfected cells were harvested every 24 h and cell viability was 
quantified using trypan blue exclusion assay. 
siRNA transfected cells were harvested after 24 h treatment and Cdk7 was IP 
(1mg) followed by kinase activity assay and Western blotting to investigate to amount of 
Cdk7 and cdk2 phosphorylation in both T98G and U87MG cells.   
Another set of cells were harvested 24h post-treatment and Western blot analysis 
with total protein (30µg) was performed to determine the expression of PKC-ι.  Total 
protein (30-100µg) was also fractionated to detect Caspase 9, cleaved Caspase 9 and 
probed for several cdk2 substrates such as pRb, p21, p27. 
Approximately, 4x103 T98G cells were grown in 96 well tissue culture plates.  
Twenty-four hour post-plating, cells were transfected with increasing concentration with 
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either PKC-ι or control siRNA (25nM-125nM) for 48h.  Cell proliferation was assessed 
using MTS assay.   
Another set of cells were harvested 24h post-treatment and Western blotting with 
total protein (30µg) was performed to determine the expression of PKC-ι and PKC-ζ.  
Total protein (30-100µg) was also separated by Western blot analysis to investigate the 
expression of several apoptotic markers such as anti-whole PARP, anti-PARP cleavage, 
anti-Caspase 3, anti-cytochrome C and anti-survivin antibodies. 
7.11. (3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) (MTS) assay. 
Approximately, 4x103 T98G cells were grown in 96 well tissue culture plates.  
Twenty-four hours post-plating, cells were transfected with either PKC-ι or control 
siRNA (25nM-125nM) for 24-48 h.  At the specific time points, cells were incubated for 
3 h with MTS reagent according to manufactures instructions (Promega).  Cell viability 
was quantified by measuring the absorbance at 490nm using a microtiter plate reader.   
7.12 Trypan blue exclusion assay. 
Approximately, 4x103 T98G cells were grown in 96 well tissue culture plates.  
Twenty-four hours post-plating, cells were transfected with either PKC-ι or control 
siRNA (25nM-125nM) for 24-48 h. At the indicated time, cells were trypsinized, 
pelleted, washed with 1ml of DPBS, resuspended in 0.4% Trypan Blue Solution, and 
counted using a hemacytometer. Live (dye excluded) cells were counted.  The results 
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from three separate independent experiments were used to determine the mean viability 
and standard deviation for each time point. 
7.13 Annexin V-FITC/PI apoptosis detection. 
The cells were stained according to the manufacturer’s instructions with Annexin 
V-FITC at room temperature for 10 minutes (Invitrogen). Following a wash with binding 
buffer, the cells were co-stained with propidium iodide and immediately analyzed via 
Canto II (BD Biosciences) and FACsDIVA software.  The number of events collected for 
each analysis was 20000. 
7.14 CFDA SE staining dilution assay. 
One day prior to siRNA transfection experiments, T98G cells were resuspended 
in 1 µM of CFDA SE solution which is commonly referred to as CFSE (Molecular 
Probes/Invitrogen) and incubated for 15 min at 37° C.  Following an incubation in 
complete medium for 30 mins, the CFSE labeled cells were seeded into 6 well plates at 
2x105 cells per well.  T98G cells were harvested at 48h post-siRNA or mock siRNA 
transfections and stained with 7-AAD (BD Biosciences) for examination by two-color 
flow cytometry of cell division and exclusion of dead cells with CFSE and 7-AAD, 
respectively.  The live gate was established by excluding the 7-AAD stained cells.  The 
number of events collected for each analysis was 20000 via Canto II and FACsDIVA 
software. 
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7.15 U.V. Irradiation. 
T98G cells were washed and resuspended in 1x PBS and seeded onto non-treated 
petri dishes for exposure to U.V. light from the U.V. transilluminator box for specified 
exposure times.  Preliminary experiments were conducted to establish the exposure times 
that were required for cell death.  After irradiation and harvesting, the cells were 
examined with Trypan blue with light microscopy and stained with Annexin V-FITC/PI 
for further analysis.   
7.16 Densitometry. 
The Intensity of each band was measured using the Quantity One, 1-D analysis 
software (BioRad Laboratories).  In order to achieve the correct intensity of each band, 
the background intensity was subtracted from the intensity of each band.  Mean 
absorbance of three independent studies were compared by means of Student’s t-test.  
p<0.05 was determined to be statistically significant. 
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